Stockwinners Market Radar for November 18, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EST NXT-ID trading halted, news pending

19:50 EST Wheeler Real Estate Investment Trust trading halted, news pending

18:52 EST Williams-Sonoma CEO sells $5.2M in common stock - In a regulatory filing, Williams-Sonoma disclosed that its CEO Laura Alber sold 40K shares of common stock on November 15th in a total transaction size of $5.2M.

18:32 EST Chicago Rivet & Machine cuts dividend to 3c from 10c per share - Chicago Rivet & Machine Co. announced that its Board of Directors declared a quarterly cash dividend of 3c per share payable December 20 to all shareholders of record on December 5. This is a 7c per share reduction from the 10c per share quarterly cash dividend that the company has declared and paid in recent quarters. The company stated that while its financial position remains sound, the Board of Directors determined that the reduction in the dividend was prudent given the company's recent operating performance. As previously disclosed, the company has been implementing multiple initiatives to improve performance that have led to year-over-year performance improvement. These include price adjustments with our customers and cost reduction projects, including the previously disclosed consolidation of the Albia, Iowa operation into the Tyrone, Pennsylvania operation. Notwithstanding, current macroeconomic headwinds exist that have impacted the company's financial performance in the most recent quarter, in particular, a significant reduction in demand from the company's automotive customers. While the company believes this to be transient, it is expected to persist into 2025, and the company is diligently pursuing strategies to develop new customer relationships and build on existing relationships in all of the markets served. With respect to the payment of future dividends, the Board of Directors will continue to consider the company's current profitability, the outlook for long-term profitability, known and potential cash requirements, and the overall financial condition of the company, and any dividend declared will be solely at the discretion of the Board of Directors.

17:55 EST HCA Healthcare exec Whalen sells 1,474 common shares - In a regulatory filing, HCA Healthcare chief ethics officer Kathleen Whalen disclosed the sale of 1,474 common shares of the company on November 14 at a price of $357.99 per share.

17:40 EST Amazon becomes exclusive retail sponsor for The Game Awards - The Game Awards announced Amazon as the exclusive retailer sponsor for the 10th Anniversary broadcast of the video game industry's biggest event, live on Thursday, December 12, 2024. As part of the multifaceted collaboration, Amazon launched a dedicated Game Awards hub page at amazon.com/thegameawards. This special TGA page will be updated with deals and offers on video game software, hardware, and accessories from now until December 31, 2024, including many TGA nominees and participating games. In addition, U.S. viewers of The Game Awards live stream can look forward to Prime exclusive limited-time offers on top video games, accessories, and hardware that will be revealed live during the show. Once revealed, these limited time offers will only be available at amazon.com/thegameawards, while supplies last. "We are thrilled to partner with the world's leading retailer to give our global audience access to special deals and offers this holiday season," said Geoff Keighley, founder/CEO, The Game Awards. "Wario 64 is going to have a busy night." Reference Link

17:18 EST Goodyear Tire awarded $134.87M Defense Logistics Agency contract - Goodyear Tire has been awarded a $134.87M firm-fixed-price requirements contract under solicitation for ground tires. This was a competitive acquisition with three responses received. These are three-year contracts with no option periods. The performance completion date is December 10, 2027. Using military services are Army, Air Force, Navy, and Marine Corps. Type of appropriation is fiscal 2025 through 2028 defense working capital funds. The contracting activity is the Defense Logistics Agency Land and Maritime, Columbus, Ohio.

17:16 EST Amentum awarded $389M Army contract modiication - Amentum was awarded a $389M modification to a contract for logistics support services. Work locations and funding will be determined with each order, with an estimated completion date of November 20, 2025. Army Contracting Command is the contracting activity.

17:06 EST Defense Metals appoints Mark Tory as CEO - Defense Metals announced the appointment of Mark Tory to the position of CEO. Tory will commence his new role January 1, 2025, and will be relocating to Vancouver. His previous executive experience includes managing director of Crescent Gold, after a period as CFO and company secretary

17:05 EST Weyerhaeuser to invest $500M in new TimberStrand facility in Arkansas - Weyerhaeuser announced its plan to invest approximately $500M to build a new TimberStrand facility near Monticello and Warren, Arkansas, expanding the company's engineered wood products, or EWP, capacity in the U.S. South. The facility will have an annual production capacity of approximately 10M cubic feet, which is comparable to the company's existing TimberStrand facility in Kenora, Ontario. Construction is expected to begin in 2025, with the goal of starting operations in 2027. The new facility will support an underserved and growing market for TimberStrand in the U.S. South. Additionally, the plant will include a biomass-fueled cogeneration system, which will fully supply the plant's electrical needs and reduce its environmental footprint. The facility doubles Weyerhaeuser's North American TimberStrand capacity. The facility is expected to generate over $100M of annual adjusted EBITDA at full operating capacity and expected to add nearly 200 jobs in Monticello and the surrounding area once fully operational. The company expects to incur approximately $500M of capital expenditures for the facility through 2027 and plans to exclude this investment for purposes of calculating the company's annual adjusted funds available for distribution, as used in its cash return framework. This capital outlay may be sourced from cash on hand or through future financing, as the company deems appropriate.

17:03 EST Supermicro up 16% at $24.92 afterhours following compliance plan announcement

16:49 EST Protagonist and JNJ say icotrokinra study for PsO meets endpoint - Protagonist Therapeutics (PTGX) announced positive topline results from its collaboration with Johnson & Johnson (JNJ), in ICONIC-LEAD1 and ICONIC-TOTAL2, two pivotal Phase 3 investigational studies of icotrokinra , the first-in-class targeted oral peptide that selectively blocks the IL-23 receptor, in individuals 12 years of age and older with moderate to severe plaque psoriasis or PsO . In the ICONIC-LEAD study, once-daily icotrokinra showed significant skin clearance versus placebo in adults and adolescents with moderate to severe plaque psoriasis. At week 16, nearly two-thirds of patients treated with icotrokinra achieved IGA3 scores of 0/1 clear or almost clear skin , and 49.6% achieved PASI 904, compared to 8.3% and 4.4% on placebo, respectively. Further increases in response rates continued to be observed at week 24, with 74.1% of patients treated with icotrokinra achieving IGA scores of 0/1, and 64.9% achieving PASI 90. Safety data was found to be consistent with the Phase 2 FRONTIER 1 and 2 studies. A similar proportion of patients experienced adverse events between icotrokinra and placebo, with 49.3% and 49.1% of participants experiencing a treatment emergent adverse event at week 16. In addition, positive topline results from the Phase 3 ICONIC-TOTAL study showed once-daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo. "These positive Phase 3 results confirm the compelling efficacy and safety trends that were observed with the previous Phase 2b FRONTIER-1 and -2 studies, highlighting icotrokinra's potential as a best-in-class oral agent providing an ideal combination of significant skin clearance with demonstrated tolerability in a once-daily pill for treating plaque psoriasis," said Dinesh V. Patel, PhD, President and CEO of Protagonist. "These results also continue to validate Protagonist's innovative peptide technology platform and its effectiveness in creating highly differentiated new chemical entities to address unmet needs in various disease areas." Under the terms of the recently amended icotrokinra license and collaboration agreement with Johnson & Johnson, Protagonist has earned $165M in milestone payments. These are inclusive of $115 million for successful completion of a Phase 3 study, a $35 Maccelerated payment previously due upon acceptance of an NDA in psoriasis, and a $15M accelerated payment previously due upon initiation of a Phase 3 study in a second indication.5 The $165M payment, which the Company expects to receive in Q1 2025, has been earned under the agreement and is not refundable. The Company remains eligible for up to $630M in future development and sales milestone payments, and tiered royalties of 6-10% on worldwide net sales.

16:42 EST Angi Inc. CEO buys $430K in common stock - In a regulatory filing, Angi Inc. disclosed that its CEO Jeffrey Kim bought 250K shares of common stock on November 15th in a total transaction size of $430K. Shares of Angi are up 3% afterhours at $1.97.

16:34 EST Coherent releases high-speed InP photodiodes for 1.6T transceivers - Coherent has announced the production release of high-speed indium phosphide InP photodiodes. Designed for use in the next generation of 800G and 1.6T transceivers with 200 Gb/s PAM4 optical lanes, and available in both singlet and 1x4 array configurations with integrated lenses, they provide efficient optical coupling and compatibility with all major 4-channel and 8-channel transimpedance amplifiers TIA . Featuring a wide optical response from 900 nm to 1650 nm and high responsivity at 1310 nm, these RoHS-compliant devices have a 3 dB bandwidth greater than 50 GHz, a low capacitance of 50 femtofarads fF , and low dark current. The photodiode arrays are available in two different flip-chip pad configurations for compatibility with high-performance TIAs and are engineered to meet the demanding requirements of longwave fiber-optic communication systems. "These photodiodes represent a major advancement in reliability and performance for data center applications," said Kou-Wei Wang, Vice President, InP DML & Photodiodes at Coherent. "Their high bandwidth and excellent optical characteristics allow our customers to develop high-speed optical transceivers with an additional performance margin." These high-speed photodiodes are currently available in sample quantities, with general availability planned for Q1 2025.

16:33 EST Northwest Natural Gas to acquire SiEnergy Operating for $273M in cash - Northwest Natural Holding Company announced it entered into an agreement to acquire SiEnergy Operating, LLC from SiEnergy Capital Partners, LLC, an affiiliate of Ridgewood Infrastructure, for $273M in cash and the assumption of $152M of debt. Upon closing the transaction, which is expected to occur in the first quarter of 2025, SiEnergy will become a wholly owned subsidiary of NW Natural Holdings. "The acquisition of SiEnergy builds on our core strength of operating utilities and delivering essential services to customers," said David H. Anderson, CEO of NW Natural Holdings. "Texas is one of the fastest growing states in the nation with a constructive regulatory and policy environment. SiEnergy has a substantial number of contracts to add new customers in the coming years. We believe we will be well positioned to capture additional growth as Texas' population expands and new housing developments provide opportunities for new customers." The transaction is expected to further support management's long-term EPS growth outlook of 4% to 6%. The transaction is expected to close in the first quarter of 2025 subject to customary closing conditions including expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. No regulatory approval is needed from the Railroad Commission of Texas to close this transaction.

16:33 EST Lancaster Colony to acquire sauce and dressing production facility for $75M - Lancaster Colony "announced their planned acquisition of a sauce and dressing production facility located in Atlanta, Georgia from Winland Foods, Inc. This asset purchase transaction is expected to close in the first quarter of calendar year 2025, subject to customary closing conditions, with a purchase price of approximately $75 million. The production facility accounts for a total of approximately 300,000 square feet, of which approximately 250,000 square feet are designated for manufacturing."

16:32 EST Incyte to pause MRGPRX2 program in CSU, suspend MRGPRX4 in CP - The company states: "Incyte announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 in chronic spontaneous urticaria, CSU. The decision was made following the observation of certain in vivo preclinical toxicology findings. These data have been shared with the U.S. Food and Drug Administration and Incyte will work closely with the FDA to determine next steps. Enrollment in the other INCB000262 proof-of-concept studies is complete and data from all clinical studies will help inform its future development and guide the potential development of back-up molecules. In addition, data from the Phase 2 study evaluating MRGPRX4 in cholestatic pruritus, CP, does not support further development."

16:26 EST AMD Chief Accounting Officer resigns - In a regulatory filing, Advanced Micro Devices disclosed that on November 15, Ms. Darla Smith informed AMD of her resignation as Corporate Vice President and Chief Accounting Officer of AMD. Effective November 18, Smith will cease serving as AMD's Chief Accounting Officer and continue her employment as Corporate Vice President until January 17, 2025 to assist with transition matters. "Smith's resignation is not the result of any dispute or disagreement with AMD, including with respect to any matters relating to AMD's accounting practices or financial reporting. On November 13, 2024, the Board of Directors of AMD appointed Mr. Philip Carter, 46, as AMD's Corporate Vice President, Chief Accounting Officer and principal accounting officer effective as of November 18, 2024. Mr. Carter previously served as Corporate Vice President, Chief Accounting Officer at Skyworks Solutions, Inc. where he had worked since February 2017," the filing stated. Reference Link

16:22 EST Rocket Pharmaceuticals has not initiated enrollment in Phase 2 RP-L301 study - In a regulatory filing, Rocket Pharmaceuticals stated: "As previously disclosed, the Company has reached agreement with the U.S. Food and Drug Administration on the study design of the Phase 2 pivotal trial for RP-L301, the Company's ex vivo LV-based program targeting Pyruvate Kinase Deficiency, a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. While the Phase 2 RP-L301 Study is ready for patient enrollment, the Company is currently focusing its resources on its other programs and has not initiated enrollment in the Phase 2 RP-L301 Study. The Company anticipates resuming patient enrollment in 2025."

16:16 EST Iron Mountain expands planned data center capacity in Virginia - Iron Mountain has acquired two data center development sites in Virginia - adding significant planned capacity to support its rapid growth in the data center market. These latest acquisitions bring more than 100 acres to Iron Mountain's data center development portfolio, and add an estimated 350+ megawatts of planned future capacity - taking the company's total data center capacity to in excess of 1.2 gigawatts globally when fully developed. Iron Mountain's acquisition of a 66-acre development site in Richmond, VA will enable it to build a new data center campus with more than 200 MW of expected capacity. The company's acquisition of a 40-acre development site in Manassas, VA enables two planned new data center buildings at its further expanded Manassas campus, offering an estimated 150 MW of additional capacity. This acquisition includes the planned development of an electricity substation to ensure continued uninterrupted power supply across the Manassas campus.

16:16 EST Armada Hoffler names Shawn Tibbetts as new CEO - Armada Hoffler's Board of Directors announces that Shawn Tibbetts, the company's COO, has been named CEO beginning January 1, 2025. Current CEO Lou Haddad will retire at the end of 2024 but will retain the role of Executive Chairman of the Company's Board of Directors. Additionally, the Board of Directors expects to appoint Tibbetts to the Board of Directors upon his elevation to Chief Executive Officer.

16:15 EST NWTN Inc. receives delisting determination from Nasdaq, intends to appeal - NWTN Inc. announced that it received a determination notice from the staff of Nasdaq informing the company that as a result of the company's failure to file its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the SEC and regain compliance with Nasdaq Listing Rule 5250 by November 11, the staff has determined that, unless the company requests an appeal by November 19, Nasdaq will suspend trading of the company's ordinary shares and warrants at the opening of business on November 21 and will file a Form 25-NSE with the SEC, which will remove the company's securities from listing and registration on Nasdaq. The determination does not result in the immediate suspension of trading or delisting of the company's securities, and the Nasdaq listing rules provide a procedure for the company to appeal the determination and seek a stay of suspension pending the appeal. Pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, the company may appeal the determination to a hearings panel, which request will stay the trading suspension for 15 days from the date of the request. When the company requests a hearing, it may also request an extended stay of the suspension, pending the hearing. The company's requests for a hearing and for an extended stay must be received by November 19. By November 19, the company intends to request for a hearing to appeal the determination, and for an extended stay of the trading suspension until the panel has rendered a decision on the appeal. The company is working diligently to file the 2023 annual report as soon as practicable. Although the company will use all reasonable efforts to regain compliance with Nasdaq Listing Rule 5250(c)(1), there can be no assurance that the company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq listing criteria. There can be no assurance that the panel will grant the company's request for continued listing or stay the suspension of the company's securities.

16:13 EST Motorola Solutions CEO sells $13.8M in common stock - In a regulatory filing, Motorola Solutions disclosed that its CEO Gregory Brown sold 28K share of common stock on November 14th in a total transaction size of $13.8M.

16:09 EST Aecom boosts stock buyback to $1B, raises quarterly dividend 18% - Aecom affirmed the priorities of its returns-based capital allocation policy. Accordingly, the company announced that its Board of Directors has approved an increase to its share repurchase authorization to $1B and an increase to its quarterly dividend by 18% to 26c per share. "The increases to our share repurchase authorization and quarterly dividend payment reflect our confidence in delivering strong earnings and cash flow growth, as well as the strength of our balance sheet," said Troy Rudd, AECOM's chief executive officer. "Through this announcement, we are affirming our returns-driven capital allocation policy focused on high-returning investments in accelerating organic growth and margin expansion, as well as capital returns to shareholders. This includes returning $2.5 billion to shareholders since 2020, primarily through share repurchases." Consistent with these priorities, the Company has bought back $2.2B of stock since the initiation of its repurchase program in September 2020, which has reduced its shares outstanding by 21%. In addition, the Company remains committed to increasing the per share value of its dividend by double-digits annually, as reflected in the 20% average annual increase it has delivered over the last three years.

16:07 EST Tuya reports Q3 non-GAAP EPS 4c vs. 2c last year - Reports Q3 revenue $81.6M vs. $61.1M last year. Xueji Wang, Founder and CEO of Tuya, commented, "I'm pleased that in the Q3, we delivered robust financial performance across all our business segments, featuring high growth, stable margins and tight operating budget control. These solid results reaffirm our position as a growing and profitable smart cloud platform leader with a clear strategy and strong execution capabilities. Our performance was driven by robust demand from existing customers, as reflected in a Dollar-Based Net Expansion Rate of 124%. We also strengthened global partnerships, particularly in Europe and emerging markets, and expanded our developer community to 1.26 million registered developers. Looking ahead, we remain focused on empowering developers and delivering innovative solutions to meet the growing demand for smart products."

16:07 EST NRx Pharmaceuticals names Michael Abrams as CFO - NRx Pharmaceuticals announced it has appointed Michael Abrams as its permanent CFO. Abrams succeeds Interim-CFO Richard Narido, who will continue to support the company's financial function and other projects. Michael Abrams is a senior finance professional with almost three decades of experience as an executive officer, investment banker, director and senior advisor, which includes serving as the CFO of Arch Therapeutics, RiseIT Solutions, and FitLife Brands.

16:05 EST Array Technologies announces $3M investment in Swap Robotics - Array Technologies announced its strategic $3M investment in Swap Robotics, a utility-scale solar robotic operations, maintenance, and automation solutions company. Swap Robotics is currently in the process of closing a pre-Series A funding round targeting strategic investors, including Array. Under the investment agreement, Array has agreed to provide two additional investments of $1M each if Swap attains certain agreed-upon milestones.

16:03 EST Grail tests first patient for TROPION-Lung12 Phase 3 study - GRAIL (GRAL) announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer, or NSCLC, ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. The study is sponsored by AstraZeneca (AZN) in collaboration with Daiichi Sankyo. The study, which is being conducted under an FDA-approved Investigational Device Exemption application, held by GRAIL, leverages GRAIL's targeted methylation platform to detect ctDNA. With GRAIL's blood-only approach, tissue analysis and bespoke panel development are not required, enabling simple integration into pharmaceutical clinical trial workflows. In TROPION-Lung12, patients will be screened with the GRAIL assay prior to surgery to inform eligibility for post-surgery randomization to an adjuvant treatment regimen (NCT06564844). Assay performance was previously reported in the Journal of Thoracic Oncology and presented at the 2023 North America Conference on Lung Cancer.

16:01 EST Adicet Bio opens enrollment for ADI-270 phase 1 clinical trial in ccRCC - The company states: "Adicet Bio announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinom, or ccRCC." "Solid tumors represent one of the highest unmet medical needs in oncology and have yet to benefit from the breakthroughs observed with CAR T cell therapies in hematologic malignancies. Emerging data from ADI-270, our armored allogeneic 'off the shelf' gamma delta 1 CAR T cell therapy targeting CD70 positive cancers, have shown potential in addressing this gap," said Chen Schor, President and Chief Executive Officer. "At the recent ASGCT conference, we presented preclinical data in which ADI-270 demonstrated significant tumor infiltration, resistance to the immunosuppressive tumor microenvironment, and potent activity via CAR and innate-mediated targeting, highlighting its potential for treating solid tumors. We look forward to enrolling patients and anticipate sharing preliminary clinical data from the trial in the first half of 2025."

15:49 EST Nvidia working with Google to accelerate design of next-gen quantum computing - Nvidia (NVDA) announced it is working with Google Quantum AI (GOOG) to accelerate the design of its next-generation quantum computing devices using simulations powered by the NVIDIA CUDA-Q platform. Google Quantum AI is using the hybrid quantum-classical computing platform and the NVIDIA Eos supercomputer to simulate the physics of its quantum processors. This will help overcome the current limitations of quantum computing hardware, which can only run a certain number of quantum operations before computations must cease, due to what researchers call "noise." "The development of commercially useful quantum computers is only possible if we can scale up quantum hardware while keeping noise in check," said Guifre Vidal, research scientist from Google Quantum AI. "Using NVIDIA accelerated computing, we're exploring the noise implications of increasingly larger quantum chip designs."

15:48 EST Nvidia announces ALCHMI NIM microservice for sustainable materials research - Nvidia announced the ALCHEMI NIM microservice that accelerates sustainable materials research by optimizing AI inference for chemical simulations that could lead to more efficient and sustainable materials to support the renewable energy transition. NVIDIA also plans to release NIM microservices that can be used to simulate the manufacturability of novel materials - to determine how they might be brought from test tubes into the real world in the form of batteries, solar panels, fertilizers, pesticides and other essential products that can contribute to a healthier, greener planet.

15:46 EST Nvidia announces availability of H200 NVL PCIe GPU - During the Supercomputing 2024 conference, Nvidia announced the availability of the NVIDIA H200 NVL PCIe GPU - the latest addition to the Hopper family. H200 NVL is ideal for organizations with data centers looking for lower-power, air-cooled enterprise rack designs with flexible configurations to deliver acceleration for every AI and HPC workload, regardless of size. Complementing the raw power of the H200 NVL is NVIDIA NVLink technology. The latest generation of NVLink provides GPU-to-GPU communication 7x faster than fifth-generation PCIe - delivering higher performance to meet the needs of HPC, large language model inference and fine-tuning. The NVIDIA H200 NVL is paired with powerful software tools that enable enterprises to accelerate applications from AI to HPC. It comes with a five-year subscription for NVIDIA AI Enterprise, a cloud-native software platform for the development and deployment of production AI. NVIDIA AI Enterprise includes NVIDIA NIM microservices for the secure, reliable deployment of high-performance AI model inference.

15:44 EST Nvidia announces new NIM microservices for climate change modeling simulation - Nvidia announced two new NVIDIA NIM microservices that can accelerate climate change modeling simulation results by 500x in NVIDIA Earth-2. Earth-2 is a digital twin platform for simulating and visualizing weather and climate conditions. The new NIM microservices offer climate technology application providers advanced generative AI-driven capabilities to assist in forecasting extreme weather events. NVIDIA NIM microservices help accelerate the deployment of foundation models while keeping data secure. NVIDIA is releasing the CorrDiff NIM and FourCastNet NIM microservices to help weather technology companies more quickly develop higher-resolution and more accurate predictions. The NIM microservices also deliver leading energy efficiency compared with traditional systems.

15:42 EST Nvidia CEO Huang says AI will drive scientific breakthroughs - During its SC24 Special Address in Atlanta, Nvidia (NVDA) announced a wave of AI and supercomputing tools set to revolutionize industries like biopharma and climate science. The announcements, delivered by Nvidia founder and CEO Jensen Huang and Vice President of Accelerated Computing Ian Buck, are rooted in the company's deep history in transforming computing, the company said. "Supercomputers are among humanity's most vital instruments, driving scientific breakthroughs and expanding the frontiers of knowledge," Huang said. "Twenty-five years after creating the first GPU, we have reinvented computing and sparked a new industrial revolution." Nvidia's journey in accelerated computing began with CUDA in 2006 and the first GPU for scientific computing, Huang said. At SC24, Nvidia announced the new cuPyNumeric library, a GPU-accelerated implementation of NumPy, designed to supercharge applications in data science, machine learning and numerical computing. Nvidia also unveiled the NVIDIA Omniverse Blueprint for real-time computer-aided engineering digital twins, a reference workflow designed to help developers create interactive digital twins for industries like aerospace, automotive, energy and manufacturing. In addition, in partnership with Google (GOOG), Nvidia's CUDA-Q now powers detailed dynamical simulations of quantum processors, reducing weeks-long calculations to minutes. With the open-source release of BioNeMo Framework, NVIDIA is advancing AI-driven drug discovery as researchers gain powerful tools tailored specifically for pharmaceutical applications. The company also announced two new microservices - CorrDiff NIM and FourCastNet NIM - to accelerate climate change modeling and simulation results by up to 500x in the NVIDIA Earth-2 platform. As demand for AI systems like the Blackwell supercomputer grows, NVIDIA is scaling production through new Foxconn facilities in the U.S., Mexico and Taiwan. NVIDIA also announced the general availability of the NVIDIA H200 NVL, a PCIe GPU based on the NVIDIA Hopper architecture optimized for low-power, air-cooled data centers.

15:40 EST Sinclair congratulates Brendan Carr on appointment as Chairman of FCC - Sinclair, Inc. President and CEO Chris Ripley issued the following statement in response to the announcement that Commissioner Brendan Carr will be named Chairman of the Federal Communications Commission: "Congratulations to Commissioner Carr on being named the next Chairman of the Federal Communications Commission. We look forward to working with him to strengthen local broadcasting by leveling the playing field and removing regulatory roadblocks that needlessly hamper investment, innovation and competition."

15:24 EST Bakkt up 48% after FT report about takeover talks with Trump Media

15:18 EST Bakkt Holdings trading halted, volatility trading pause

14:53 EST BorgWarner VP Demmerle sells $748K in company shares - VP of BorgWarner Stefan Demmerle disclosed the sale of 21,500 shares of company stock on November 14 at $34.79 per share for a total transaction amount of $748,077.

14:14 EST nVent Electric collaborating with Nvidia on AI-ready liquid cooling solutions - nVent Electric (NVT) announced that it is collaborating with Nvidia (NVDA) to deploy liquid cooling solutions at scale supporting the NVIDIA GB200 NVL72 and next-generation platforms. "The collaboration is expected to deliver cutting-edge, built-to-spec liquid cooling technology to enhance the performance and energy efficiency of NVIDIA-powered data centers. nVent is a leader in liquid cooling, providing resilient and sustainable solutions for the next generation of computing supporting AI demand. nVent is contributing to active development programs with hyperscale and high-performance computing - HPC - customers, delivering customized liquid cooling solutions that support NVIDIA NVL36 and NVL72 deployments. nVent worked with NVIDIA to define a reference architecture that utilizes nVent's coolant distribution unit, liquid-to-air heat exchanger and manifold products. This helps data center designers save time during design and implementation, while delivering the capability to cool high-compute-density data centers," the company stated.

13:53 EST Beacon jumps 12% to $110.40 after WSJ says QXO made takeover bid

13:40 EST NHTSA probing over half million Fords for loss of engine power, seatbealts - The National Highway Traffic Safety Administration said it opened an investigation into 456,565 Ford Bronco Sports and Ford Mavericks for loss of engine power accompanied by complete electrical system failure. The agency also opened an investigation into 112,567 2019-2020 Expeditions over alleged seat belt retractor pretensioner inadvertent deployment, resulting in loss of seat belt pretensioner protection and seat belt remaining in a locked position.

13:10 EST Petrobras trading resumes

12:49 EST Cracker Barrel urges holders to back company's director nominees - Cracker Barrel Old Country Store urgers shareholders to vote the universal White proxy card "FOR ONLY" Cracker Barrel's 10 recommended director nominees "to protect the value of their investment; continue the momentum of the Company's strategic transformation plan; and ensure Cracker Barrel remains a beloved and relevant restaurant brand for many years to come." The Annual Meeting of Shareholders will be on November 21 and shareholders on record as of September 27 are entitled to vote at the meeting, the company noted.

12:47 EST Petrobras announces 2025-2029 business plan proposal - Petrobras announced that the proposal for the 2025-2029 business plan was deliberated by its Executive Board. The proposal for the 2025-2029 business plan that will be considered by the board foresees, for the company's next five-year cycle: Total investments of $ 111B, with $77B in the exploration and production segment, total production projection of 3.2M barrels of oil and gas equivalent per day; Projection of ordinary dividends with a range starting at $45B and flexibility for extraordinary payments of up to $10B during the plan period.

12:36 EST Petrobras trading halted, news pending

12:13 EST Netflix says Beyonce to perform at halftime during NFL Chrstimas Day game - Netflix announced that Beyonce will take the field as the halftime performer during NFL Christmas Gameday, streaming live on Netflix on Wednesday, December 25. The performance will take place during the second of Netflix's two Christmas Day games, as the Houston Texans host the Baltimore Ravens at NRG Stadium at 4:30 PM ET. In case you missed it, Netflix is the global home of the NFL's two Christmas Day marquee games: The Super Bowl LVII-winning Kansas City Chiefs will face the Pittsburgh Steelers live on Netflix at 1p.m. ET; then at 4:30 PM ET, the Baltimore Ravens will take on the Houston Texans. In keeping with the NFL's long-standing holiday tradition, the Netflix Christmas Day games will air on broadcast TV in the competing team cities and be available on U.S. mobile devices with NFL+. With Netflix and Beyonce, the NFL kicks off what is expected to be a new holiday tradition, as Netflix has also announced NFL games for 2025 and 2026, the company said. Reference Link

12:00 EST Nuscale Power rises 15.3% - Nuscale Power is up 15.3%, or $3.51 to $26.52.

12:00 EST a.k.a. Brands rises 20.3% - a.k.a. Brands is up 20.3%, or $3.48 to $20.63.

12:00 EST Direxion Daily Junior Gold Miners Index Bear 3x Shares falls -11.2% - Direxion Daily Junior Gold Miners Index Bear 3x Shares is down -11.2%, or -$3.37 to $26.80.

11:25 EST BridgeBio reports open-label extension data on acoramidis in ATTR-CM - BridgeBio Pharma presented initial outcomes from the ATTRibute-CM open-label extension study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions. ATTRibute-CM was designed to evaluate the efficacy and safety of acoramidis, an investigational, near-complete, orally-administered, small molecule stabilizer of TTR. The preliminary results from this ongoing OLE study were also simultaneously published in Circulation. The OLE study involves 330 participants who completed the 30-month ATTRibute-CM Phase 3 study. Key initial results from the OLE study, presented by Dr. Judge at AHA, show that continuous treatment with acoramidis led to: A confirmed sustained improvement relative to placebo in time to first event starting at Month 3 in ATTRibute-CM; A statistically significant reduction in ACM alone of 36% by Month 36 and 34% by Month 42, as assessed by the Stratified Cox proportional hazards model; A significant reduction of composite ACM and CVH by 46% at Month 36 and 48% at Month 42 as assessed by negative binomial regression, building upon the previously presented 42% reduction at Month 30 in ATTRibute-CM; Evidence of early benefit in patients who crossed over from placebo to acoramidis after Month 30 as compared to extrapolated placebo curve reinforces the early separation seen previously in ATTRibute-CM; Acoramidis continues to be well tolerated, with no new clinically significant safety signals identified in this long-term evaluation. The OLE data build on previously reported results from ATTRibute-CM in which acoramidis demonstrated clinically important treatment effects on mortality, CVH, and quality of life, further supporting that greater transthyretin stabilization can improve clinical outcomes for patients. This included a 50% reduction in the cumulative frequency of CVH relative to placebo at Month 30.

11:20 EST BAE Systems announces $202M in U.S. Navy contracts - BAE Systems has received $202M in U.S. Navy contracts to provide modernization and maintenance services aboard the guided missile destroyer USS Laboon and the amphibious assault ship USS Wasp, the company announced. BAE Systems shipyard personnel and their subcontractor teammates will begin working aboard both ships next February and March, respectively.

11:09 EST Mallinckrodt presents data on Terlivaz for injection in patients with HRS - Mallinckrodt announced a poster presentation on TERLIVAZ for injection in patients with hepatorenal syndrome with rapid reduction in kidney function at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases, taking place in San Diego, CA, from November 15-19, 2024. TERLIVAZ is an FDA-approved product indicated to improve kidney function in adults with HRS with rapid reduction in kidney function, an acute and life-threatening condition requiring hospitalization. HRS involving rapid reduction in kidney function is estimated to affect more than 42,000 Americans annually, approximately 0.01% of the U.S. population, making it a very rare condition; and rates of hospitalizations are increasing. The poster presentation includes a pooled patient cohort analysis from the CONFIRM, REVERSE, and OT-0401 Phase 3 studies of TERLIVAZ.5 The research evaluated HRS reversal among patients on Day 4 after 12 doses of TERLIVAZ. TERLIVAZ treatment is recommended at a dose of 1 mg every six hours for up to 14 days, which can be escalated on Day 4 to 2 mg every six hours if the patient's serum creatinine has decreased from baseline but by less than 30%.5 In the analysis, most patients who achieved HRS reversal by the end of treatment required continuation of therapy beyond Day 4. The rate of HRS reversal by the end of treatment was 33.6% in the TERLIVAZ group and 16.8% in the placebo group. Most patients who achieved HRS reversal with TERLIVAZ received greater than12 doses, and 5.1% received less than or equal to12 doses before discontinuation. There appeared to be significantly more patients who achieved HRS reversal in the TERLIVAZ group who received greater than12 doses, but not among those who received less than or equal to12 doses; however, based on the design of the analysis, statistical methodology did not control for confounding variables, thus the p-values are nominal. The limitations of this study include, but are not limited to, small sample sizes, variables in methodology, and possible errors and omissions within the data sets.

11:05 EST Rocket Pharmaceuticals announces publication of Phase 1 RP-A501 long-term data - Rocket Pharmaceuticals presented long-term safety and efficacy results from the Phase 1 RP-A501 study which showed that RP-A501 was generally well tolerated and all evaluable Danon disease patients demonstrated LAMP2 protein expression at 12 months and reduction of left ventricular mass index by greater than or equal to10% at 12 months after treatment. These data were presented today at a Late-Breaking Scientific session at the American Heart Association Scientific Sessions 2024, published in The New England Journal of Medicine and discussed on a company webinar today at 12:00 p.m. ET. The safety and preliminary efficacy of RP-A501 was evaluated in a single-arm, open-label, multi-center Phase 1 study in male patients with Danon disease. Five patients were treated with the low dose and 2 adult/adolescent patients were treated with the high dose. Data from the Phase 1 study showed that RP-A501 in conjunction with a transient immunomodulatory regimen was generally well tolerated. Most adverse events were mild or moderate in severity, assessed as not related to RP-A501, and non-serious. All RP-A501 or immunomodulatory regimen-related AEs were manageable or reversible. One patient had worsening heart failure at baseline attributed to Danon disease and required heart transplantation for cardiomyopathy progression five months after receiving RP-A501. Evidence of sustained clinically meaningful improvement was observed in pediatric patients followed up to 24 months and adult/adolescent patients followed up to 60 months. All evaluable patients in the Phase 1 trial demonstrated: Cardiac LAMP2 protein expression at 12 months and thereafter; Reduction or stabilization of LV mass index - the median reduction from baseline to most recent visit of 24%; Preservation of normal LV ejection fraction; Reduction or stabilization of cardiac biomarkers; Improvement in New York Heart Association class from Class II at baseline to Class I at most recent follow-up visit; NYHA Class I reflects the absence of clinical signs of heart failure; Improvements in Kansas City Cardiomyopathy Questionnaire quality-of-life scores that persisted up to 54 months of follow-up; and Preliminary long-term follow-up assessments for Patient 1001 were positive for immunohistochemical staining and appear to show Grade 3 expression in the heart at the five-year timepoint. These are preliminary results with a formal update to be presented at an upcoming medical conference in 2025.

10:12 EST Trex Company appoints Anand Kangala as CIO - Trex Company (TREX) announced that Dr. Anand Kangala, has joined Trex as its new Vice President and Chief Information Officer. As a member of the Trex leadership team, Dr. Kangala will lead global IT functions and enterprise technology strategy. Most recently, Dr. Kangala served as Senior Director at Home Depot (HD), where he launched a Transformation Management Office and led the digital strategy to build the foundation for interconnected retail vision through advanced technology and data-driven insights.

10:07 EST Lennox enters partnership with Contractor Commerce - Lennox announced a partnership with Contractor Commerce. Through this partnership, Lennox Residential HVAC will provide its Lennox Premier Dealer network with exclusive e-commerce capabilities, including transparent pricing for HVAC systems and filter subscription services that benefit both homeowners and dealers. Contractor Commerce's platform will seamlessly integrate with the Lennox dealer network. Lennox Premier Dealers will be featured prominently on the Lennox Dealer Locator, with direct links for consumers to purchase Lennox filters and subscribe to regular deliveries, ensuring the right filter is available at the right time. Homeowners will also be able to look up system estimates, allowing dealers to display their own individual pricing, enabling consumers to compare options and purchase directly from dealers' websites or online filter stores.

10:04 EST Penguin Solutions enters collaboration with Dell Technologies - Penguin Solutions (PENG) announced its collaboration with Dell Technologies (DELL) to deliver complete AI solutions that accelerate customers' time to value through validated, high-performing AI infrastructure. These end-to-end Penguin OriginAI solutions combine Dell PowerEdge AI-optimized servers, Dell PowerScale storage and Dell PowerSwitch data center switches with Penguin's validated solution architectures. When enhanced by Penguin's ClusterWare intelligent cluster management software and supported by Penguin's expert AI and high-performance computing infrastructure services - GPU cluster deployment and management are simplified while driving increased performance and availability.

10:00 EST Palantir falls -8.2% - Palantir is down -8.2%, or -$5.39 to $60.38.

10:00 EST Zeekr rises 8.9% - Zeekr is up 8.9%, or $1.81 to $22.15.

10:00 EST Valhi rises 13.1% - Valhi is up 13.1%, or $3.16 to $27.29.

09:48 EST Direxion Daily Junior Gold Miners Index Bear 3x Shares falls -7.1% - Direxion Daily Junior Gold Miners Index Bear 3x Shares is down -7.1%, or -$2.13 to $28.04.

09:48 EST Brady falls -10.1% - Brady is down -10.1%, or -$7.50 to $66.72.

09:47 EST Knightscope Inc trading halted, volatility trading pause

09:47 EST Hyster-Yale Materials rises 8.9% - Hyster-Yale Materials is up 8.9%, or $4.74 to $57.91.

09:41 EST Fort Products enters agreement with digital developer for AI-based app - Jeffs' Brands' Fort Products has entered into an agreement with a digital developer for the development of an innovative AI-based mobile application for pest control solutions offered by Fort. The mobile application will offer users a comprehensive pest control solution, utilizing advanced AI technology for pest identification and tailored treatment recommendations. It is expected that the mobile application will be available to customers during the first half of 2025. Key features of the app will include: AI-Powered Identification: To identify pests and receive instant insights. Personalized Solutions: Recommendations for natural, chemical, and DIY pest control methods. Product Suggestions: Fort-managed recommendations to enhance user outcomes. Cross-Platform Support: Compatible with both iOS and Android devices. Admin Panel: Enables Fort to dynamically manage product offerings.

09:38 EST United Bancorp Alabama repurchases all common stock held by 401(k) plan - United Bancorporation of Alabama announced that it has completed the repurchase of all of its shares of common stock held by the United Bancorporation of Alabama, Inc. 401(k) Employee Stock Ownership Plan. All 197,717 shares of United common stock held by the KSOP were repurchased at $54.25 per share, for an aggregate purchase price of approximately $10.7 million

09:37 EST iLearningEngines announces delay in release of Q3 financial results - iLearningEngines announced a delay in the release of its third-quarter 2024 financial results. As previously announced, a Special Committee of the Board of the Directors has been formed to conduct an independent investigation into assertions contained in a recent short seller report.While the Investigation is ongoing, based on preliminary information identified by the Audit Committee of the Board of Directors during the course of the Investigation, that is subject to change with the completion of the Investigation, the audited consolidated financial statements of iLearningEngines Holdings, a wholly owned subsidiary of the Company as of December 31, 2023 and 2022 and for each of the three years in the period ended December 31, 2023, which were reported in the Current Report on Form 8-K filed by the Company on April 22, 2024, the audited consolidated financial statements of Holdings, as of December 31, 2022 and 2021 and for each of the three years in the period ended December 31, 2022, which were reported in the registration statement on Form S-4 initially filed by the Company with the U.S. Securities and Exchange Commission on September 5, 2023 and declared effective on February 2, 2024, in connection with the Company's business combination, the Company's unaudited financial statements for the quarter ended June 30, 2024, Holdings' unaudited financial statements for the quarter ended March 31, 2024, which were reported in the Super 8-K, and Holdings' unaudited financial statements for the quarters ended June 30, 2022, September 30, 2022, June 30, 2023 and September 30, 2023, which were reported in the S-4, as previously filed with the SEC, should no longer be relied upon. At this time, the Company is unable to determine whether it must correct financial statements for the Non-Reliance Period, or if such corrections are necessary, the quantification of such corrections. If the Investigation concludes that financial statements in the Non-Reliance Period must be restated, the Company intends to diligently pursue completion and filing of such restated financial statements as soon as reasonably practicable. In addition, the Company is working diligently towards the goal of being in a position to file third-quarter 2024 financial results with the SEC as soon as practicable after the conclusion of the Investigation, but at this time cannot predict with certainty when the preparation and filing of information will be completed. The Company will release additional information concerning the Investigation in due course and is committed to taking appropriate measures to improve its internal controls.

09:35 EST iLearningEngines names Thomas Olivier interim COO - iLearningEngines announced the appointment of Bonnie-Jeanne Gerety as Interim CFO and the appointment of Thomas Olivier as Interim COO. Farhan Naqvi will continue to serve ILE as Senior Vice President of Corporate Development. Olivier is a Managing Director with Arrowroot Capital and has held this position since March 2021. In addition, from November 2020 to April 2024, Mr. Olivier served as the President and CFO, and the Vice Chairman of the board of directors of Arrowroot Acquisition Corp.

09:32 EST MCB withdraws proposal to acquire Whitestone REIT - MCB Real Estate sent a letter to the Board of Trustees of Whitestone REIT withdrawing MCB's previously announced proposal to acquire the company. MCB sent the following letter to the Whitestone Board: "MCB Real Estate delivered an attractive, fully-financed proposal to the Whitestone Board to acquire Whitestone for $15 per share in an all-cash transaction... The Board's refusal to grant due diligence, engage in any meaningful discussions, or commence a strategic alternatives process is not consistent with its duties and indicates a boardroom culture of entrenchment. While we continue to believe our proposal is the best path forward for shareholders, our attempts to engage have been rebuffed at every turn, so we are withdrawing our proposal to acquire Whitestone at this time... When pressed on whether the Board is open to opportunities to enhance value on Whitestone's third quarter 2024 earnings call, Whitestone CEO David Holeman falsely asserted that the Board is actively looking at strategic options... Given the Board's refusal to engage with us regarding our proposal or conduct a process to explore whether other parties may have an interest in transacting with Whitestone, Mr. Holeman's comments are at best a naive sidestep to the question, and at worst a downright lie to shareholders... As we have said from the onset of this process, our interests are aligned with other Whitestone shareholders. Whitestone shareholders deserve a board that is committed to considering all opportunities to maximize value. If the Whitestone Board continues its pattern of delay and entrenchment, MCB believes the entire Board should be removed at the next annual meeting of shareholders... While we are withdrawing our proposal at this time, we remain a significant shareholder of the company and will continue to consider all options available to MCB and other Whitestone shareholders to ensure that the Board upholds its responsibilities."

09:31 EST Globalstar to transfer listing to Nasdaq, announces reverse stock split - Globalstar announced its intent to transfer its common stock listing to Nasdaq in the first quarter of 2025. In connection with this planned uplisting, the company also announced that its board of directors has authorized a reverse stock split of its common stock, which is also expected to take place in the first quarter of 2025 at a ratio to be determined closer to the effective date. The reverse stock split is intended to align trading fundamentals with peers, improve liquidity and attract greater investment participation from a more diverse and larger set of institutional investors. Globalstar has submitted its application to list on the Nasdaq and the company is working with Nasdaq to complete the transfer in connection with the effective date of the reverse stock split. The company's common stock will continue trading on the NYSE American until the uplisting is complete.

09:21 EST Vision Marine Technologies partners with pontoon manufacturer Smoker Craft - Vision Marine Technologies announced a new production initiative with Smoker Craft. This collaboration is expected to produce a state-of-the-art pontoon platform specifically designed to integrate Vision Marine's high-performance electric propulsion systems, specifically the pontoon-designed P-Powerpack. We believe the powerpack will merge technology and exceptional craftsmanship into a transformative product for the marine industry. Vision Marine and its manufacturing partner will leverage their combined expertise to redefine electric pontoon capabilities. Smoker Craft manufacturing facilities provide precision engineering, laser cutting technology, and stringent quality control, making it an ideal collaborator to bring Vision Marine's innovative E-Motion 180E Electric Powertrain to market with high efficiency and craftsmanship. This new pontoon platform, intended primarily for rental operations, boat clubs and commercial applications, exemplifies Vision Marine's commitment to delivering high-voltage electric propulsion solutions that are both scalable and accessible. The collaboration is expected to enable Vision Marine to meet increasing market demand and provide rental operators with a high-performance electric boating option, setting a precedent for broader adoption and sustainable growth across the industry.

09:18 EST Array Technologies appoints two executives to lead EMEA region - Array Technologies appointed Leonardo Serpa as general manager, Europe, the Middle East, and Africa - EMEA - and Hector Sanchez as vice president of sales, EMEA. Serpa joins ARRAY after serving as CEO at Essentia Energia. Sanchez was previously the vice president of sales for Soltec Trackers. Before Essentia Energia, Serpa served as CEO at Engie Solutions and previously held multiple key leadership positions at ABB.

09:16 EST Gladstone Commercial announces industrial acquisition in St. Clair, Missouri - Gladstone Commercial has acquired a 124,500 square foot industrial manufacturing, distribution, and warehouse facility in St. Clair, Missouri. Gladstone Commercial acquired the property subject to a 20-year absolute NNN lease to ATRO, LLC, a leader in manufacturing durable and high-performance heavy-duty polyurethane truck parts that extend the lifespan of truck components and reduce the total cost of ownership for fleet operators.

09:15 EST Rail Vision unveils active control system, enabling semi-autonomous capabilities - Rail Vision announced an advancement in railway safety and control. Developed in collaboration with a major U.S.-based rail company, Rail Vision's new system transitions from passive warning systems to active safety systems that directly control locomotive throttle and brakes, setting a new step towards autonomous rail operations. This next-generation capability, tailored for shunting yard locomotives, leverages Rail Vision's proprietary AI technology to provide real-time insights integrated into the customer's locomotive control systems. The system will be deployed as part of the initial rollout on the customer's U.S. fleet, with implementation starting by the end of 2024. This advancement signals a significant transition from passive warning Advance Driver Assistance Systems to the active control of the throttle and brakes which is done in real-time for autonomous applications in order to mitigate risks and preserve business continuity.

09:14 EST Mullen Automotive's Class 4 truck granted rebate voucher in California - Mullen Automotive announced that the California Air Resources Board has approved Bollinger Motors all-electric Class 4 truck, the 2025 Bollinger B4, for the Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project. The HVIP program accelerates commercialization by providing point-of-sale vouchers to make advanced vehicles more affordable while driving commercial technology transformation. To date, the program has funded more than 12,000 clean vehicle purchases. Under HVIP, the 2025 Bollinger B4 EV truck, with a suggested MSRP of $158,758, now qualifies for up to a $60K cash voucher. When combined with the available $40K federal tax credit, the net effective cost of the B4 could be less than $59K.

09:12 EST Massimo expands partnership with Rural King for 2025 - Massimo announced the expansion of its successful retail partnership with Rural King, a leading farm and home store with locations across the U.S. After an outstanding year offering Massimo Motor's selection of go-karts to Rural King customers, both companies are excited to expand this partnership in 2025. The expanded program will introduce a wider range of Massimo products available both online and in-store, including UTVs, ATVs, go-karts, golf carts, and mini bikes.

09:11 EST Vital Farms releases limited-edition 'Gingerbread Farmhouse Kit' - Vital Farms is pecking the halls and raising the standards of a classic baking tradition this year with the new Gingerbread Farmhouse Kit. The limited-edition kits, made in partnership with Supernatural and King Arthur Baking Company, are filled with everything you need to bake, build, and decorate a gingerbread barn using high-quality ingredients from this trio of premium brands. Contents include Vital Farms pasture-raised egg and butter coupons, gingerbread and icing mixes from King Arthur Baking, plant-based and dye-free sprinkles, melting morsels, and food colorings from Supernatural, hen and cow cookie cutters, and piping bags. An approachable barn blueprint with directions and a tutorial video can help anyone avoid a #PinterestFail. Gingerbread Farmhouse Kits are now available to purchase online for $65, while supplies last

09:09 EST Avalon launches 'BrAce for Impact' affiliate marketing program - Avalon GloboCare announced the launch of the "BrAce for Impact" affiliate marketing program for KetoAir, a handheld breathalyzer device equipped with AI-enabled software and Hot App shareable technology, specifically designed for ketogenic health monitoring. The "BrAce for Impact" affiliate marketing program was developed in response to demand from attendees at the Hack Your Health Conference and the Keto Pa-LOU-za Conference. The program offers an attractive discount and commission structure, enabling affiliates to provide a coupon code and earn commissions on each sale. This structure encourages KetoAir promotion through social media, helping spread awareness among a wide audience. Affiliates in the program will receive support in the form of professionally designed graphics and marketing materials, along with access to KetoAir's brand tags and logos for authentic health journey updates. This initiative targets metabolic coaches, podcasters, health authors, experts, disease management and reversal companies, and other influencers.

09:07 EST EverCommerce announces enhancements to SaaS-based solution suite - EverCommerce announced a series of enhancements to its SaaS-based solution suite. These enhancements coincide with "Small Business November," a month-long celebration honoring the many small and medium sized businesses and their respective owners that serve as the backbone of our economy. In conjunction with Small Business November, EverCommerce is announcing several product enhancements in its EverPro home and field services vertical, including: EverProEdge: An add-on product that is bringing cash-back rewards on purchases service-based SMBs are already making for its business. In addition to helping customers improve profitability by providing rewards that reduce material costs over time, EverPro Edge customers get tailored content directly in the platform geared toward equipping customers with insights to improve operational efficiency, secure more deals, and make smarter business decisions - all of which are intended to drive sustained growth and success. Payments: New digital payment methods for customers, giving them online invoicing, digital wallets and online payments options helping small businesses focus on getting new sales rather than securing payment for work already done. EverCommerce customers can now use programs such as Text-To-Pay which provides customers with an easy-to-use link within a text message that provides an online invoice and allows payment right from a mobile phone and additional digital payment options which provide an easy way for homeowners to pay - EverPro customer data shows better than 30% growth in payment amount per transaction for these payment methods over traditional ones. Operations Improvements: Expense tracking and new estimating/invoice templates for Joist customers, improved reporting for Fieldpoint and ServiceFusion customers and a new mobile calendar in Kickserv showing real-time contractor availability. AI: AI enhancements that help customers seamlessly compile data that can pinpoint issues more quickly and provide more accurate insights that can help inform decision-making in marketing, customer service and payments. These enhancements help service-based SMBs save countless hours that can be put toward other projects, maximizing efficiency.

09:07 EST SEI Investments selected by Brown Advisory to launch ETF - SEI announced that Brown Advisory selected the Advisors' Inner Circle Fund series trust as its operational platform to launch the Brown Advisory Flexible Equity ETF, the firm's first ETF. A fundamental active strategy focused on U.S. companies, Brown Advisory's Flexible Equity ETF is managed by a tenured team with an existing footprint in mutual funds and separately managed accounts.

09:06 EST Dell Technologies announces Dell AI factory advancements - Dell Technologies continues to make enterprise AI adoption easier with the Dell AI Factory, expanding the world's broadest AI solutions portfolio. Powerful new infrastructure, solutions and services accelerate, simplify and streamline AI workloads and data management. "Getting AI up and running across a company can be a real challenge," said Arthur Lewis, president, Infrastructure Solutions Group, Dell Technologies. "We're making it easier for our customers with new AI infrastructure, solutions and services that simplify AI deployments, paving the way for smarter, faster ways to work and a more adaptable future."

09:05 EST Caravelle International Group regains compliance with Nasdaq min bid price - Caravelle International received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules.

09:05 EST PPG teams with SARO/Siccardi to expand powder coatings presence in Italy - PPG announced a strategic partnership with SARO/Siccardi, the largest distributor of powder coatings in Italy. The collaboration will strengthen PPG's distribution network for powder coatings in the Italian market and broaden customer access to high-quality products and services...Under the partnership, PPG and SARO/Siccardi will work closely with customers to gain a better understanding of their unique requirements and provide tailored solutions, technical support and competitive pricing. "We are confident that this partnership will elevate our services to meet the growing demand for powder coatings," said Justin Epler, PPG general manager, Industrial Coatings, EMEA. "With our advanced powder coating technologies and SARO/Siccardi's extensive distribution network, our customers in Italy will have access to a more comprehensive selection of high-quality products and faster access to our solutions." "Access to PPG warehouses, laboratories and production facilities in Italy will improve our customer service and response times," said Roberto Siccardi, general manager, SARO/Siccardi.

09:03 EST Safe Bulkers announces stock repurchase program up to 5M shares - Safe Bulkers has authorized a program under which it may from time to time in the future purchase up to 5,000,000 shares of the Company's common stock. If the maximum number of shares of the Company's common stock are purchased pursuant to the aforementioned program, it would represent approximately 4.7% of the shares of the Company's common stock outstanding and 8.7% of its public float.

09:01 EST Hanmi Financial opens Korea representative office in Seoul - Hanmi Financial announced that Hanmi Bank opened its first representative office in Seoul, South Korea. The new representative office is located within the International Finance Center Seoul. This complements the bank's existing Korea Desks in Los Angeles, Orange County, San Diego and Silicon Valley in California, and in cities in New York, New Jersey, Georgia and Texas.

08:59 EST Zeta Global CEO, leadership team to purchase $3M of common stock - Zeta Global announced that David Steinberg, Zeta's co-founder, chairman and CEO, members of the company's leadership, and members of the board of directors intend to purchase shares of Zeta's Class A common stock on Monday, November 18. Taken together, these intended purchases by Steinberg and other members of Zeta leadership in their personal capacity and the directors represent approximately $3M of Zeta's Class A common stock.

08:57 EST Tharimmune presents clinical data on TH104 for chronic pruritus - Tharimmune presented new TH104 clinical data at the American Association for the Study of Liver Disease The Liver Meeting 2024, underway in San Diego from November 15-19. The Phase 1 trial was a single-dose, single-center, open-label, randomized study of TH104 transmucosal buccal film conducted in two cohorts of patients with chronic liver disease, with the primary outcome of safety and tolerability. Data presented at The Liver Meeting include adverse events as well as an assessment of patients' relief of pruritus symptom scores when correlated to pharmacokinetics of TH104. Patients with cholestatic liver disease and a known history of persistent generalized pruritus for at least 4 weeks prior to screening were included. After an overnight fast of 10 hours, subjects received a single low dose of TH104. Serial blood samples for PK analysis were taken, and patients were monitored for itch severity scores utilizing the Worst-Itch Numerical Rating Scale, a relevant clinical outcome assessment for pruritus in chronic liver disease, and for itch intensity over a 24-hour period. Pruritus is common in most liver diseases and the WI-NRS is a validated numerical rating scale displaying 11 numbers ranging from 0, representing "no itch," to 10, representing "worst imaginable itch," and patients are asked to pick the number corresponding to the intensity of their pruritus. Results from multiple large studies support the usefulness and validity of WI-NRS for evaluating change over time in clinical trials. Pearson's correlation coefficient was used to assess the correlation between TH104 concentration Area Under the Curve and the change in WI-NRS score 48 hours after dosing. This study screened 19 patients and 12 were enrolled with two types of CLD categorized as Child-Pugh A and Child-Pugh B. The Child-Pugh score is a system for assessing the prognosis and necessity of transplant in CLD that provides a forecast of the increasing severity of a patient's liver disease and expected survival rate. The score is determined by scoring clinical measures of liver disease and the possibility of eventual liver failure, with Class A indicating mild liver disease and Class B indicating moderate liver disease with one-to-five-year survival rates of 95% and 75%, respectively. There were no patients enrolled in this study with the most severe Child-Pugh C classification. The correlation coefficient between TH104 AUC and change in itch, r, was 0.7060, with a p-value of 0.0103 and a 95% confidence interval for r of 0.2220 to 0.9108. The mean baseline WI-NRS scores in Groups A and B were 4.33 and 6.17, respectively, translating to moderate-to-severe chronic pruritus at the start of the study. The mean baseline itch score for all 12 subjects was 5.25. At one-hour post-dosing with TH104, Group A and Group B had a mean decline in WI-NRS scores of 26.8% and 19.0%, respectively, and continued to decline two hours post-dose by 42.3% and 21.7%, respectively. Both cohorts continued to improve in mean itch scores at the four-hour and eight-hour time points, including the combined total subjects. At 24-hours post dosing, Group A and Group B achieved a mean decline of 30.7% and 35.2%, respectively, in pruritus scores. The mean reduction in itch scores for all 12 subjects 24 hours after a single dose of TH104 was 33.3%. A total of two AEs were reported in two subjects over the course of the study. These AEs were mild and possibly related to study drug, with no serious adverse events reported. There were no deaths or other significant adverse events reported during the entire study. There were no new adverse events during the study, with events correlated with previous studies and a safety profile consistent with the literature for the active ingredient in TH104.

08:54 EST Cosmos Health integrates bitcoin, ethereum as treasury reserve assets - Cosmos Health has adopted a strategy to include Bitcoin and Ethereum as part of its treasury reserve assets. The adoption of this new policy follows the Company's forward-thinking approach to investing in new technologies, including the recent acquisition of Cloudscreen, its AI-driven drug repurposing platform. The Company expects that adding Bitcoin and Ethereum, along with potentially other cryptocurrencies and blockchain-related assets, will help diversify its balance sheet and offer significant upside potential as these assets increasingly gain global adoption. In addition to holding Bitcoin and Ethereum as treasury reserve assets, the Company is also working to accommodate customers who wish to make payments in cryptocurrencies.

08:52 EST Complete Solar's Blue Raven signs installation agreement with Sunder Energy - Complete Solar's Blue Raven Solar division has signed an installation sales agreement with Sunder Energy, a residential sales companies in the US. Sunder sells solar in 48 states, executing approximately 12,000 solar installations per year, generating estimated revenue of $400M annually for residential installers.

08:50 EST Celularity resolves Nasdaq listing compliance issue - Celularity announced that the Nasdaq Listing Qualifications Hearings Panel has cancelled the hearing regarding Celularity's non-compliance with Nasdaq Listing Rules as the company has cured its filing delinquency. The matter is now closed, and Nasdaq has confirmed that Celularity's stock will continue to be listed and traded on The Nasdaq Stock Market. Celularity filed its Form 10-Q for the period ended March 31 on October 16, and its Form 10-Q for the period ended June 30, on November 7, achieving compliance with Nasdaq requirements.

08:48 EST Foremost Clean Energy signs agreement with Red Cloud Financial Services - Foremost Clean Energy has entered into a strategic agreement with Red Cloud Financial Services, an arms-length independent contractor, to provide promotional services, including advice on marketing, communications and social media activities. Under the engagement, Red Cloud will be paid a fee of $10K per month effective October 14, for a twelve-month term which automatically renews month-to-month thereafter. Red Cloud will review and advise on non-deal road shows, review, draft and advise on traditional marketing documents, make introductions to, meet and communicate with corporate analysts, institutional and professional investors and retail brokers, provide traditional media support and assist in the creation of content for Red Cloud's exclusive RCTV platform and dissemination of content via RCTV, and other services as required by the company. There are no performance obligations contained in the Agreement and Red Cloud will not receive common shares, stock options or any form of equity in the company as compensation. Red Cloud is an IIROC regulated dealer and a leading provider of financial services to the global mining sector, with headquarters in Toronto, Canada

08:46 EST Pineapple Energy announces corporate name change to SUNation Energy - Pineapple Energy announced that it has begun the effectuation of the change to its corporate name to SUNation Energy, Inc. by filing its Certificate of Incorporation with the Secretary of State of Delaware under our new name, and that the Company will begin trading on Nasdaq under the trading symbol "SUNE" on November 19th, 2024.

08:44 EST Stifel Financial appoints Brad Edgar as lead healthcare equity trader - Stifel Financial announced the hiring of Brad Edgar as Managing Director and Lead Healthcare Equity Trader. He is based in the firm's New York office and reports directly to R.J. Grant, Head of Global Equity Trading at Stifel. Edgar joins Stifel from Seven Grand Managers, where he served as Partner, responsible for all risk execution and trading of the firm's equity portfolio.

08:44 EST Artelo Biosciences to present key data on 3 development programs - The company states: "Artelo Biosciences announced that Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo, will be presenting at the 7th Cannabinoid-Derived Drug Development Summit. The event will take place November 18-20, 2024, at the Wyndham Beacon Hill Hotel in Boston, MA. Key data from Artelo's development programs will be highlighted in three separate sessions titled: Fatty Acid-Binding Protein 5 Inhibitors as Novel Therapeutics (featuring ART26.12); ART27.13: A Peripherally Selective CB1/CB2 Agonist for Cancer Cachexia; ART12.11: A Novel Cannabidiol Cocrystal Demonstrating a Pharmacokinetic Profile Comparable to Epidiolex(R) in Rats."

08:43 EST Edible Garden appoints Dario Pressimone as VP, digital and e-commerce - Edible Garden announced that Dario Pressimone has joined the Company as Vice President of Digital and E-Commerce. Prior to joining Edible Garden, Dario has served in marketing and digital marketing roles at leading retailers such as Macy's and Bed Bath & Beyond. In his new role, Dario will lead Edible Garden's e-commerce and digital marketing initiatives, focusing on expanding the company's online presence and enhancing customer engagement. His strategic vision will be key to strengthening Edible Garden's commitment to providing fresh, organic produce and innovative food products to a growing consumer base.

08:42 EST Foxo Technologies to hold special meeting of shareholders - FOXO Technologies will hold a Special Meeting of its Shareholders at 10.30am EST on Friday, November 29, 2024. The Board of Directors of the Company has authorized a virtual meeting of its shareholders to be held on Friday, November 29, 2024, at 10:30 a.m. Eastern Standard Time to approve several proposals. The record date was November 15, meaning that all shareholders of record on November 15, 2024, will be entitled to vote on the approvals requested. The Company has several approvals it requires from its shareholders as a result of transactions entered into and plans to hold this Special Meeting, followed by an Annual General Meeting for 2024, details of which will follow in the coming weeks. At the Special Meeting, shareholders will be asked to vote on the following approvals on November 15, 2024, as amended. Shareholder Proposals: 1. Until recently the Company was at risk of the trading price of its Class A Common Stock falling below the $0.10 minimum requirement for NYSE American continued listing requirements and the Board of Directors determined it was prudent and necessary to ask the shareholders to approve a reverse stock split of our issued and outstanding Class A Common Stock any time before September 30, 2025, at a ratio ranging from one-for-five to one-for-one hundred with the exact ratio within such range to be determined at the sole discretion of the Company's Board of Directors, without further approval or authorization of our stockholders before the filing of an amendment to the Certificate of Incorporation effecting the proposed Reverse Split. In the event the Company's share price does not risk triggering the $0.10 minimum requirement for NYSE American continued listing requirements the Board of Directors may decide not to complete a reverse split. 2. The Company has entered into an Exchange Agreement with a debt holder who it has been unable to repay, and the Company desires to have the debt holder exchange their debt to equity. The Company is asking its shareholders to approve, for purposes of complying with NYSE American Rule 713, the issuance of shares of Class A Common Stock in an amount equal to or in excess of 20% of our Class A Common Stock that was outstanding immediately prior to the Exchange Agreement when it was entered into but not exceeding 11,288,568 shares. The debt outstanding was approximately $1,945,000 at September 30, 2024. The quantity and value of Class A Common Stock the Company will be required to issue will be related directly to the debt exchanged to equity on the date exchanged. 3. The Company has entered into an agreement with ClearThink Capital Partners, LLC that will give the Company access to a $5 million Equity Line of Credit the Company can draw on if needed to support the business objectives of the Company. The Company is asking its shareholders to approve, for purposes of complying with NYSE American Rule 713, the issuance of shares of Class A Common Stock in an amount equal to or in excess of 20% of our Class A Common Stock outstanding immediately prior to such issuance in connection with the Strata Purchase Agreement dated October 13, 2023 with ClearThink Capital Partners, as supplemented by the Supplement to Strata Purchase Agreement, dated as of October 13, 2023, and as amended, with ClearThink Capital Partners, whereby ClearThink agreed to purchase up to $5,000,000 of shares of our Class A Common Stock and in connection with the Finder's Fee Agreement, dated as of October 9, 2023, as amended, with J.H. Darbie & Co., Inc., a registered broker-dealer but not exceeding 40,000,000 shares. The quantity and value of Class A Common Stock the Company will be required to issue will be related directly to the cash it draws from the Equity Line of Credit, if used, on the date drawn 4. The Company entered into an agreement with an institutional investor to receive up to $2.5 million in debt funding. The Company has received $1 million at this time and is asking its shareholders to approve, for purposes of complying with NYSE American Rule 713, the issuance of shares of Class A Common Stock in an amount equal to or in excess of 20% of our Class A Common Stock outstanding immediately prior to such issuance in connection with the Securities Purchase Agreement with an institutional investor pursuant to which the Company agreed to issue to the Purchaser and subsequent purchasers who will also be parties to the SPA Senior Notes in the aggregate principal amount of up to $2,800,000 but not exceeding 30,800,000 shares. The quantity and value of Class A Common Stock the Company will be required to issue will be directly to the value of debt converted to equity on the date concerted. 5. To approve the adjournment of the Special Meeting, if necessary or advisable, to solicit additional proxies in favor of the foregoing proposals if there are not sufficient votes to approve the foregoing proposals; and 6. Such other matters as may properly come before the Special Meeting or any lawful adjournment or postponement thereof.

08:40 EST Jet.AI to regains compliance with Nasdaq listing rules - Jet.AI has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1). As previously disclosed, the Company received a letter on December 1, 2023, notifying the Company that its amount of stockholders' equity had fallen below the $10 million minimum stockholders' equity requirement. The Company's stockholders' deficit as of December 31, 2023, was $(3,963,039). The notification of noncompliance had no immediate effect on the listing or trading of the Company's Common Stock. Initially, the Company had 180 calendar days, or until May 29, 2024, to regain compliance with the Minimum Equity Requirement. Although the Company did not regain compliance with the Minimum Equity Requirement by May 29, 2024, the Nasdaq Hearings Panel determined to provide the Company until November 26, 2024, to regain compliance with the Minimum Equity Requirement after the Company elected to transfer the listing of its Common Stock to The Nasdaq Capital Market on August 14, 2024. To regain compliance, the minimum stockholders' equity of the Company must meet or exceed $2.5 million. Since the Nasdaq Hearings Panel provided the Company with an extended time period to regain compliance with the Minimum Equity Requirement, the Company has completed the following transactions listed in the Form 8-K filed on November 18, 2024. As a result of these transactions described in the Form 8-K filed on November 18, 2024, and with approximately $4.0 million in shareholders' equity and cash and cash equivalents of $3.6 million, the Company believes it has stockholders' equity above the $2.5 million Minimum Equity Requirement. Therefore, the Company believes it has regained compliance with the Minimum Equity Requirement. As of November 18, 2024, there were 839,733 shares of the Company's common stock, par value $0.0001, issued and outstanding.

08:38 EST Cassava Sciences appoints Freda Nassif as Chief Commercial Officer - Cassava Sciences announced the appointment of Freda Nassif as Chief Commercial Officer, effective today. "I am thrilled to expand Cassava's leadership team and welcome Freda Nassif as Chief Commercial Officer. She joins our company at a critical time, ahead of the release of topline results from RETHINK-ALZ, our first Phase 3 trial for simufilam, expected by the end of 2024, and potential product launch," said Rick Barry, President and Chief Executive Officer. "Freda brings to Cassava a proven track record of successfully developing and implementing effective commercial strategies for innovative medicines. Pending positive simufilam Phase 3 results and FDA approval, we believe Freda's extensive expertise will be invaluable to the development of a robust commercial plan. She will play a key role in helping to realize our ambitious goal of reimagining the treatment possibilities for Alzheimer's disease."

08:36 EST Schrodinger gets additional funding to expand toxicology risk initiative - Schrodinger announced that it is broadening and accelerating its initiative to expand the company's computational platform to predict toxicology risk early in drug discovery. The goal of the initiative, announced earlier this year, is to develop a computational solution designed to improve the properties of novel drug development candidates and reduce the risk of development failure associated with binding to off-target proteins, which can be associated with serious side effects. In conjunction with this expansion, Schrodinger received an additional $9.5M from the Bill & Melinda Gates Foundation, which follows the initial $10M grant from the Gates Foundation in July 2024. The additional funding enables Schrodinger to more rapidly access relevant experimental structures and extends the funding for this initiative to April 2026. Once developed, the technology will be available to the Gates Foundation's grantees around the world to help speed the development of new drugs against diseases that disproportionately affect people in low- and middle-income countries. These tools will also be available to Schrodinger's software customers and will be used to advance Schrodinger's proprietary drug discovery programs and collaborations. "This additional funding allows us to accelerate and broaden the scope of our initiative to rapidly develop high-quality computational models to address off-target toxicity, a significant cause of drug development failure," stated Ramy Farid, Ph.D., chief executive officer at Schrodinger. "We are grateful to the Gates Foundation for their continued support and shared vision of using computation to reduce the potential for safety issues in preclinical and clinical research and significantly lower the cost and risk of drug development." The majority of revenue associated with the additional funding is expected to be recognized in 2025.

08:35 EST Ispire Technology, IKE Tech announce pre-PMTA submission meeting with FDA - Ispire Technology and IKE Tech, a joint venture among three leading technology and research companies Ispire, Touch Point Worldwide d/b/a Berify and Chemular, announced a successful in person pre-PMTA, Pre-Market Tobacco Product Application, submission meeting with FDA's Center for Tobacco Products, CTP, for their Age Verification technology, designed to allow adult access to electronic nicotine delivery systems, ENDS, while preventing youth access to such products at point-of-use. This critical regulatory milestone marks an important step in the journey to provide an innovative, secure universal solution aimed at preventing youth access to ENDS and expanding the market for adults who choose to use flavored PMTA-authorized products. The IKE Tech Identity and Age Verification technology unlocks opportunities for adults who choose to use flavored vapor products while introducing a pioneering approach to reducing youth access and usage.

08:33 EST Nevro announces publication of new data on Nevro1 SI Joint Fusion System - Nevro announced the publication of new data in Medical Devices: Evidence and Research, which demonstrate the superiority of the Nevro1 SI Joint Fusion System, a posterior integrated transfixation cage system offering enhanced stability, minimized bone removal and increased fusion potential compared to a posterolateral cylindrical threaded single-implant system. Nevro1's performance also showed that it is equivalent in osteopenic bone when compared to a lateral triangular rod system in healthy bone. Results concluded: Nevro1 and the lateral triangular rods produced equivalent motion reduction in all motion planes. Posterolateral cylindrical threaded implant produced less motion reduction than Nevro1 and lateral implants in flexion-extension. Using Nevro1 for the treatment of SI joint-related pain allows for the most surface area for fusion, which provides a significantly better opportunity for robust SI joint arthrodesis.

08:32 EST Ekso Bionics to showcase device technology in 'AI for Good' Webinar - Ekso Bionics Holdings announced that Katherine Strausser, Principal Controls Engineer at Ekso Bionics, will be participating in an 'AI for Good' webinar. The webinar, entitled "AI-powered Exoskeletons Revolutionizing Rehabilitation and Mobility", will take place on Tuesday, November 19 at 10:00 a.m. ET. The session will explore the latest exoskeleton technologies and challenges, illustrating how these technologies are not just assisting in overcoming physical limitations but are paving the way for a new era in medical rehabilitation.

08:31 EST Intensity Therapeutics presents INT230-6 Phase 1/2 daya in Sarcoma - Intensity Therapeutics announced that Christian Meyer M.D., Ph.D., Assistant Professor of Oncology and lead medical oncologist for adult sarcoma patients at Johns Hopkins University's Sidney Kimmel Cancer Center, presented final safety and efficacy data from the Company's Phase 1/2 clinical trial of INT230-6 that was used as a monotherapy in patients with relapsed, refractory, and metastatic sarcomas, along with an overview of the Company's ongoing INVINCIBLE-3 Study design. Phase 1/2 Study: Efficacy: The mOS in the mixed sarcoma population: 21.3 months for INT230-6; The mOS had not been reached with 21.4 months of median follow-up for patients who received a cumulative INT230-6 dose volume that was greater than 40% of their total tumor burden INT230-6 extended overall survival in refractory sarcoma subjects by nearly 15 months as monotherapy when compared to a synthetic control group based on the Royal Marsden Hospital scoring method; Sarcoma population's overall disease control rate: 93.3% at 2 months; Median duration of response: 4.0 months and 11.3 months for subjects who received a cumulative dose of greater than or equal to 40% of the total incoming total tumor burden INT230-6 demonstrated an increase in T-cells within the tumors. 27% of patients had uninjected tumors shrink, though tumors less than 1 cm were uninjected, untracked and unreported by investigators, so the true abscopal percentage is unknown; further radiomics work is on-going; Safety: INT230-6 demonstrated a favorable safety profile and was well-tolerated; 3 subject had one or more drug regimen-related Grade greater than or equal to 3 Treatment Emergent Adverse Events; all were grade 3

08:28 EST Galectin Therapeutics presents three abstracts at AASLD 2024 Liver Meeting - Galectin Therapeutics announced the presentation of three posters on the ongoing NAVIGATE trial in patients with MASH cirrhosis and portal hypertension at the American Association for the Study of Liver Diseases's annual meeting 2024 Liver Meeting, being held November 15-19, 2024 in San Diego, California. "We are excited to share latest clinical data from our ongoing NAVIGATE trial of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis and portal hypertension. We show that a centralized evaluation system can be designed for consistent and effective assessment of esophageal and gastric varices, which is critical for advancing clinical research in this population with high unmet need. We also provide an in depth look at baseline characteristics of the patient enrolled in our NAVIGATE trial," said Khurram Jamil, M.D., Chief Medical Officer of Galectin Therapeutics. "In another key finding, our research reveals that among patients with compensated MASH cirrhosis with reduced platelet counts and radiologic signs of portal hypertension, approximately one-third have detectable esophageal varices upon screening. These findings underscore the need for reliable screening and targeted therapies in this vulnerable patient population. These clinical data are of great importance as we look forward to sharing the readout of our NAVIGATE trial before the end of the year."

08:27 EST Allarity reports progress in Phase 2 stenoparib trial - Allarity Therapeutics provided a corporate update highlighting three significant developments: extended treatment duration for patients in its ongoing Phase 2 stenoparib trial, a strengthened cash position supporting initiation of a follow-up FDA registrational trial, and new revenue-generating activities from Allarity's laboratory services. Two patients in Allarity's Phase 2 clinical trial of stenoparib for advanced, recurrent ovarian cancer have now been on treatment for over 14 months, a remarkable duration of benefit given the heavily pretreated status of these patients. This extended duration further reinforces the potential of stenoparib as a promising treatment option for advanced ovarian cancer patients who have already undergone multiple lines of therapy, including prior PARP inhibitors. With a cash balance of $18.5 million as of September 30, 2024, Allarity Therapeutics is well-positioned to advance its clinical development programs. This solid financial foundation enables the Company to confidently initiate the next trial to advance stenoparib toward FDA registration. Allarity Therapeutics is also pleased to announce that its in-house Allarity Medical Laboratory has expanded from solely focusing on supporting internal drug development to securing external service agreements, with multiple biotech companies now leveraging the Company's advanced gene expression and diagnostic capabilities. This important expansion positions Allarity Medical Laboratory as a direct provider of revenue-generating, high-precision genomic services, establishing it as a valuable complementary asset for the Company. These service agreements include contracts for both Drug Response Predictor analysis and comprehensive gene expression services, reflecting Allarity's leading technology and ability to provide insights to other innovators in the biotech field. The revenue generated from such agreements significantly reduce Allarity's overall laboratory cost base while advancing the position of Allarity's proprietary DRP platform within the industry and supporting broader scientific advancements in oncology.

08:25 EST Brera Holdings says valuations soar in Italy's Serie B Pro Football League - Brera Holdings analyzed data from Transfermarkt, which shows that, from June 15, 2024, to November 12, 2024, the market values of Italian Serie B clubs and players have surged. However, the 2024/25 season has also exposed challenges for certain teams, with declines in club valuations reflecting the competitive and financial hurdles faced by Serie B clubs in Italy. Given that Brera Holdings announced in September 2024 that it signed an exclusive letter of intent to acquire an Italian Serie B club, it is excited about the overall positive trends across the league. As of November 12, 2024, several teams in Serie B have seen notable changes in their roster valuations: Pisa Sporting Club saw a 68.6% increase, with their valuation rising from EUR 27.35M in June 2024 to EUR 46.1M in November 2024. Carrarese Calcio 1908 recorded a 151% jump, going from EUR 5.25M to EUR 13.18M, highlighting their promising future after a strong start to the season. SS Juve Stabia, newly promoted from Serie C, saw their valuation increase by 146.7%, from EUR 4.23M to EUR 10.43M, underlining the excitement around their ascent. Cesena FC also performed well with a 143.4% increase, climbing from EUR 9.4M to EUR 22.88M, driven by their strong performance that currently places them 4th in Serie B standings, behind Pisa Sporting Club, US Sassuolo, and Spezia Calcio. Other clubs like Modena FC, Spezia Calcio, and Brescia Calcio have shown consistent growth, while teams such as UC Sampdoria and US Salernitana 1919 have faced significant club valuation declines, reflecting their struggles on and off the pitch.

08:24 EST Anixa Biosciences initiates third cohort in CAR-T clinical trial - Anixa Biosciences announced that it has dosed its first patient in the third cohort in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor-T cell therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center.

08:23 EST Corteva announces intent to partner with bp - Corteva (CTVA) announced a collaboration with bp (BP) on the companies' shared intent to form a crop-based biofuel feedstock joint venture, JV. The JV envisaged by Corteva and bp would produce and deliver crop-based biofuel feedstocks to help meet the anticipated growth in demand for 'sustainable aviation fuel'. "This partnership is proof positive that agriculture can continue to be part of the solution to the world's decarbonization opportunities, including by leveraging Corteva's technology, global scale, and unique grower relationships. We are excited at the prospect of partnering with bp to help the European airline industry become more sustainable while giving farmers a new source of income," said Corteva Chief Strategy Officer, Brook Cunningham.

08:21 EST NeuroBo Pharmaceuticals announces relignment, change name - NeuroBo Pharmaceuticals (NRBO) announced a strategic realignment, ahead of important clinical milestones, with a corporate name change to "MetaVia Inc.," which will be effective on November 29, 2024. In parallel, the Company's common stock will begin trading on the Nasdaq Stock Market under the new ticker symbol, "MTVA," which is expected to be operative as of the Effective Date. As part of its corporate name change, the company will also launch a new website, metaviatx.com, and a new company logo, on the Effective Date.

08:20 EST Sagimet Biosciences presents clinical denifanstat, preclinical FASN inhibitor da - Sagimet Biosciences announced the presentation of Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase inhibitor denifanstat, and preclinical data demonstrating potential benefit of FASN inhibition in atherosclerosis, at the American Association for the Study of Liver Disease - The Liver Meeting 2024, November 15-19, 2024 in San Diego, California. A poster titled "Denifanstat significantly improves liver fibrosis in difficult-to-treat MASH patients - Results from conventional and AI-based pathology from the phase 2b FASCINATE-2, a 52-week randomized, double-blind, placebo-controlled trial," was presented by Rohit Loomba, M.D., M.H.Sc., Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, and Director, MASLD Research Center, University of California San Diego, the primary investigator of the FASCINATE-2 trial. Denifanstat treatment improved fibrosis by greater than or equal to 1 stage without worsening of MASH in the higher-risk patient subgroups described below. Observed improvements by conventional pathology reading included: F3 population: 49% denifanstat vs 13% placebo; GLP1 receptor agonist population: 42% denifanstat vs 0% placebo; Type 2 diabetes population: 40% denifanstat vs 19% placebo; PNPLA3 I148 carrier population: 30% denifanstat vs 6% placebo;Strong consistency in fibrosis improvement was observed between conventional and AI-based pathology in the F3 population. Denifanstat treatment improved fibrosis by greater than or equal to 1 stage in more than 50% of F3 patients as follows: AI-based: 62% denifanstat and 26% placebo; Conventional: 55% denifanstat and 26%; An oral presentation titled "AI-based digital pathology shows that denifanstat improves multiple parameters of fibrosis and reduces progression to cirrhosis in MASH patients with F2/F3 fibrosis - results of the FASCINATE-2 study," was presented by Mary Rinella, M.D. In this analysis, second harmonic generation microscopy AI-based digital pathology was used to evaluate pre- and post-treatment liver biopsies. Denifanstat showed statistically significant liver fibrosis improvement, particularly in the portal and peri-portal regions. Improvement was observed with AI-based digital pathology not only in patients with greater than1-stage fibrosis improvement but also in patients with "no change" in fibrosis stage by conventional reading, representing important mechanistic insights provided by the AI-based platform. Select fibrosis parameters in the periportal and portal regions are part of AI-based composite score that have been recently linked to liver outcomes and mortality. Overall, both AI and conventional pathology readings demonstrated denifanstat's strong anti-fibrotic activity in MASH patients, including those with high risk of progression. These data reflect the unique mechanism of action of denifanstat and support the initiation of phase 3 trials. Lastly, a poster titled "Fatty acid synthase inhibitor reduces atherosclerosis development in diet-induced dyslipidaemia LDL receptor knockout mice with MASH," was presented by Wen-Wei Tsai, Ph.D. In this mouse model, treatment with a FASN inhibitor that is a preclinical surrogate for denifanstat rapidly reduced circulating cholesterol, triglycerides and inflammatory markers associated with atherosclerosis, including CCL4 and CXCL2. The FASN inhibitor also reduced total atherosclerotic lesion area in the aortic root and improved liver steatosis, inflammation and fibrosis. These preclinical results suggest that a FASN inhibitor such as denifanstat could potentially provide benefits in cardiovascular as well as liver health, supporting the clinical evaluation of denifanstat for long term outcomes in MASH patients.

08:17 EST Aclaris Therapeutics enters global license agreement with Biosion - Aclaris Therapeutics has entered into an exclusive license agreement with Biosion for worldwide rights to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-clinical stage, novel bispecific antibody that is directed against both TSLP and IL4R. In a completed Phase 2a, single-arm, proof-of-concept trial in the United States in 22 patients with moderate to severe atopic dermatitis, BSI-045B was observed to have a pharmacodynamic, safety and efficacy profile that could position it as a potential best-in-class therapy. BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion's regional partner, Chia Tai Tianqing Pharmaceutical Group, targeting both severe asthma and chronic rhinosinusitis with nasal polyps, accelerating the potential to show proof-of-concept across additional indications. Biosion is a global biotechnology company that has built a pipeline of innovative biologics through its internally derived proprietary technologies. Concurrent with the Biosion transaction, Aclaris has made two key additions to its leadership team: Hugh Davis, Ph.D., joins as President and COO, bringing over 35 years of experience in biologics development, clinical pharmacology, and business development from leadership roles at Biosion, Frontage, GSK, and Johnson & Johnson. Steven Knapp, PharmD, joins as Executive Vice President, Head of Regulatory & Quality, with over 35 years of regulatory and quality experience from senior positions at Biosion, Antares, Valeant, and BMS.

08:15 EST Novartis, Radio Therapeutics enter license, collaboration agreement - Ratio Therapeutics entered today into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis. The collaboration leverages Ratio's radioligand therapy discovery and development expertise as well as its technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer. Under the terms of the agreement, Ratio will receive combined upfront and potential milestone payments up to $745m, and is eligible to receive tiered royalty payments. Ratio will collaborate with Novartis to drive preclinical activities to research and select an SSTR2-targeting development candidate. Novartis will assume responsibility for all remaining development, manufacturing, and commercialization activities.

08:13 EST Genius Group launches Bitcoin Treasury with purchase of 110 bitcoin - Genius Group had completed the purchase of 110 Bitcoin for $10 million, at an average price of $90,932 per Bitcoin. The purchase follows the Company's announcement on November 12 of its "Bitcoin-first" strategy in which it is committing 90% or more of its current and future reserves to be held in Bitcoin, with an initial target of $120 million in Bitcoin. The $10 million of Bitcoin purchased since the announcement is the first of ongoing purchases the Company intends to make towards its target. Roger Hamilton, Genius Group's CEO will be hosting a Podcast as part of its Bitcoin & Blockchain Education Series at 9.00am Eastern Time on Tuesday, November 19.

08:12 EST Landsea Homes signs 14,725-square-foot long-term lease in Irving, Texas - Landsea Homes has signed a 14,725-square-foot long-term lease at Tower 1320 in Irving, Texas, which will serve as the company's Dallas-Fort Worth division headquarters, at 1320 Greenway Drive.

08:11 EST Contineum announces FDA authorization for PIPE-791 - Contineum announced authorization of its investigational new drug, or IND, application from FDA for PIPE-791 for the treatment of chronic pain associated with two separate indications, osteoarthritis, or OA, and low back pain, or LBP. PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor. The exploratory Phase 1b, randomized, double-blind, placebo-controlled, crossover, multi-center study is expected to begin in the first quarter of 2025. The company expects to enroll approximately 40 patients at up to five sites, and a treatment duration of 28 days. Contineum anticipates topline data from the PIPE-791 Phase 1b chronic pain study in early 2026.

08:10 EST Sunrise Realty Trust commits $23M in subordinate loan for Excel Miami Apartments - Sunrise Realty Trust has committed $13.0 million to a $26.0 million subordinate loan for the development of the Excel Miami Apartments, a 24-story multifamily tower located at 1550 NE Miami Place in Miami's Art & Entertainment District. An affiliated entity committed the remaining $13.0 million of the total loan amount. Centennial Bank provided a $68.5 million senior construction loan, with Jay Brito orchestrating the senior loan transaction. The Sponsor is Clearline Real Estate, a real estate investment and development firm led by Jenny Bernell. Clearline is headquartered in New York and Miami and focuses on multifamily real estate investments across growing U.S. regions. Excel Miami Apartments is designed to blend modern living with the vibrant artistic culture of downtown Miami. The development was envisioned by design architect Arquitectonica, elevating the standard of multifamily architecture in the area with a sleek, contemporary aesthetic. The Project will total 214,183 rentable square feet, with 427 apartments offering studio, one-bedroom, two-bedroom and 13 townhouse loft units. The building's amenity floor will feature 18' ceilings and includes a pool, yoga deck, fitness room, co-working space, screening room and podcast suites. Located near the Metromover School Board Station, Excel offers a transit-friendly lifestyle in the heart of Miami, making it an ideal option for professionals seeking convenience and connectivity.

08:10 EST Actinium highlights development updates for Iomab-B, Actimab-A, Iomab-ACT - Actinium Pharmaceuticals highlighted recent regulatory and development updates for its Iomab-B, Actimab-A and Iomab-ACT ARC clinical programs as well as its financial results for the third quarter ended September 30, 2024. Iomab-ACT is a next-generation CD45 targeted conditioning agent being developed for cell and gene therapies for both malignant and non-malignant hematologic indications. Actimab-A Regulatory and Development Update: Actinium met with the FDA in the third quarter and aligned with the FDA on an operationally seamless randomized Phase 2/3 trial to study Actimab-A + CLAG-M; Actinium continues to evaluate and develop additional Actimab-A clinical trials under its CRADA with the NCI, investigator initiated, or Actinium sponsored studies; Actimab-A selected by NCI for recently opened myeloMATCH precision medicine program for patients with AML and myelodysplastic syndrome. Iomab-ACT Program Update: In the third quarter, the FDA cleared the investigational new drug applications for both the commercial CAR-T study led by the University of Texas Southwestern and the sickle cell trial being led by Columbia University; Commercial CAR-T sales exceeded $3.5 billion in 2023 with multiple CAR-T therapies approved for patients with lymphomas, leukemias and multiple myeloma Columbia University sickle cell transplant trial to study Iomab-ACT for targeted conditioning prior to BMT for the first time in a non-malignant hematology setting, which is a rapidly growing indication for BMT; patient enrollment expected to commence in the first half of 2025. Iomab-B Regulatory Status and Program Update: Actinium is seeking a U.S. strategic partner to advance clinical development of Iomab-B including the Phase 3 trial; Head-to-head Phase 3 trial to enroll adult patients aged 18 and above with active AML with blasts counts greater than 5% and less than 20%, representing a broader patient population than that in the SIERRA trial

08:08 EST Sharps Technology regains Nasdaq listing compliance - Sharps Technology announced that on November 13, 2024, the Company was notified by the Nasdaq Stock Market that the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Stock Market, as set forth in Nasdaq Listing Rule 5550(a)(2) as of November 5, 2024.

08:07 EST Azek in Western U.S. distribution deal with Capital Lumber, no terms - Azek is pleased to announce a new strategic distribution partnership with Capital Lumber... This collaboration will enhance the accessibility of AZEK's industry-leading product portfolio, supporting the Company's growing market presence throughout the region, including Arizona, California, Colorado, Idaho, Nevada, Oregon, Utah, and Washington..."We are thrilled to partner with Capital to bring our products to more customers across the Western United States. This partnership complements our nationwide network of trusted distributors, further strengthening our ability to deliver premium products and exceptional service," said Jonathan Skelly, President of Residential and Commercial for AZEK. "By leveraging Capital's extensive distribution network and dedicated sales team, we are poised to strengthen our momentum and enhance brand awareness. Together, we aim to drive our businesses forward, fostering growth and success in 2025 and beyond." ..."Capital shares our dedication to providing exceptional service to our customers, fostering collaboration, and driving continuous improvement. We look forward to cultivating this new relationship with their team and ours," concluded Skelly.

08:06 EST Spire announces CFO Rasche to step down, Woodward to succeed - Spire announced that Steve Rasche will step down as executive vice president and chief financial officer effective Jan. 1, 2025. He will continue to serve as a senior adviser until his retirement on April 1, 2025. Adam Woodard, Spire's vice president and treasurer, will succeed him as executive vice president and chief financial officer effective Jan. 1, 2025.

08:05 EST Helius Medical announces exploration of strategic alternatives - Helius Medical Technologies has initiated a process, in consultation with its financial and legal advisors, to explore a range of strategic alternatives focused on maximizing stockholder value. The deferral of a reimbursement payment determination for the PoNS Controller and inadequate PoNS Mouthpiece pricing issued by CMS in October has limited the Company's ability to advance its operations and impeded its access to traditional financing avenues. Helius has engaged B. Riley Securities to act as a financial advisor in connection with the strategic review process. All potential strategic alternatives to maximize value, including an acquisition, merger, reverse merger, other business combination, sale of assets, licensing, and other strategic transactions, will be explored. No updates on the process are expected to be provided during the evaluation period unless and until the Board of Directors has concluded that disclosure is appropriate or required.

08:03 EST Enphase Energy begins shipments for IQ Battery 5Ps produced in the U.S. - Enphase Energy announced initial shipments of IQ Battery 5Ps produced in the United States that can help projects qualify for the Domestic Content Bonus Credit. The Domestic Content Bonus Credit is a tax credit that aims to encourage manufacturing and clean energy deployments in the United States as part of the Inflation Reduction Act. The domestic content bonus tax credit is only available to commercial asset owners, which includes commercial businesses adding solar and PPA/lease providers who own residential solar and battery projects. Projects using Enphase microinverters and batteries supplied from contract manufacturing partners in the United States, as well as a small amount of additional U.S.-made solar racking equipment, could qualify for the tax credits.

07:52 EST VivoPower's Tembo secures full on road homologation VTA for Tembo Tusker - Tembo E-LV has secured full on road homologation vehicle type approval for Tembo Tusker 100% electric utility vehicles across the Australia market. The approval secured by Tembo makes the Tusker only the second full electric ute to receive full on-road homologation in Australia. Tembo is currently in the process of securing similar clearance for Tuskers in New Zealand.Tembo will now seek to fast-track its strategy of bringing the Tuskers to other markets where it has customers and partners, including the United Arab Emirates, Africa, Europe, Asia, and Canada, amongst others.

07:49 EST Volatus Aerospace secures DAIR Green Fund grant - Volatus Aerospace has been awarded a grant of up to $75,000 from the Downsview Aerospace Innovation and Research Green Fund to develop and integrate an on-board "detect and avoid" system to deconflict drones from other aircraft, enabling a major step forward in safe and scalable beyond visual line of sight operations. This funding, supported by the Government of Canada through the Federal Economic Development Agency for Southern Ontario, aligns with Volatus' mission to drive sustainable growth in the aerospace sector. Building on the recent merger with Drone Delivery Canada, Volatus' engineering focus has shifted toward technologies with immediate commercial potential. The DAA system, combined with Volatus' recent installation of Kongsberg Geospatial's IRIS Terminal in its Operations Control Center for comprehensive airspace awareness, raises the bar for drone operations, accelerating the path to commercial scalability by providing a robust foundation for BVLOS capabilities. The DAA solution will minimize the need for ground-based human intervention, allowing for more complex, extended routes while maintaining stringent safety standards. By enhancing airspace awareness through the IRIS Terminal, Volatus is rapidly unlocking new operational possibilities and expanding commercial applications of its drone fleet.

07:44 EST Interactive Strength to exhibit CLMBR at Athletic Business Show - Interactive Strength announced that the Company will be exhibiting CLMBR to focus on Military and College/High School accounts at the Athletic Business Show on November 19-22 in New Orleans, Louisiana.

07:42 EST Steakholder Foods signs six commercial LOIs with international players - Steakholder Foods signed six Letters of Intent with international companies. These agreements reflect the market demand and commercial viability for Steakholder's 3D printing systems and proprietary plant-based premixes for alternative proteins. The company received three prestigious awards at the Plant-Based World Expo. The six LOIs span various international markets. Each agreement involves the anticipated sale of the company's advanced 3D printing systems and/or proprietary premix blends, a combination that enables partners to produce high-quality, scalable plant-based foods.

07:38 EST Canoo partners with the UK's Northside Truck & Van for repair services - Canoo announced a new service, maintenance, and repair - SMR - agreement with Northside Truck & Van, an automotive service provider in the U.K. With a current aftersales portfolio of over 280 garages in the country, Northside will provide support and maintenance of Canoo's light commercial vehicles for commercial fleet and government customers including 24/7/365 maintenance service availability in the U.K. Northside will also source parts inventory directly from Canoo for customer usage leveraging the company's 72 physical locations across England, Scotland and Wales.

07:37 EST Vertiv Holdings raises cash dividend 50% from 10c to 15c per share - Reflecting the company's strong financial performance and cash flow, Vertiv's Board of Directors has raised its regular annual cash dividend by 50% from 10c to 15c per share, to be declared and paid quarterly. The increase will be effective starting with the fourth-quarter cash dividend of 3.75c per share of Class A common stock, which was declared by the Board of Directors on November 18, and is payable on December 19 , to shareholders of record of Class A common stock at the close of business on December 3.

07:37 EST Zimmer Biomet announces CE Mark certification for knee system - Zimmer Biomet received the CE Mark for its Persona Revision Knee System. This addition to the Persona family builds on Zimmer Biomet's commitment to personalized solutions, providing surgeons with advanced tools for revision knee arthroplasty. "After the successful introduction of Persona Revision Knee in the United States and other markets, the CE Mark certification and commercial launch extends its availability significantly so that more surgeons have access to an innovative solution that can enhance patient outcomes," said Joe Urban, President, Knees at Zimmer Biomet.

07:35 EST Cabaletta Bio announces updated clinical data on CABA-201 - Cabaletta Bio announced new and updated clinical data on CABA-201 demonstrating the potential to achieve drug-free, compelling clinical responses based on eight patients dosed across the ongoing Phase 1/2 RESET-Myositis, RESET-SLE and RESET-SSc clinical trials. These data were presented in oral and poster presentations at the American College of Rheumatology Convergence 2024, which is being held at the Walter E. Washington Convention Center in Washington, D.C. from November 14-19, 2024. Cabaletta designed CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, to deeply and transiently deplete CD19-positive B cells following a one-time infusion that may enable a reset of the immune system with the potential for durable remission without chronic immunosuppressive therapies in patients with autoimmune diseases. Cabaletta is currently evaluating CABA-201 in the RESET clinical development program across five company-sponsored clinical trials that each have disease-specific cohorts with six patients per cohort. All cohorts are evaluating the same single, weight-based dose of CABA-201 at 1 x 106 cells/kg without a dose escalation requirement. Treatment with CABA-201 in each clinical trial includes a preconditioning regimen of fludarabine and cyclophosphamide, consistent with the dosing regimen used in the third-party academic studies, except for the RESET-PV trial which is evaluating CABA-201 without preconditioning. New and Updated Clinical Data Summary: As of the data cut-off date of November 1, 2024, eight patients had been dosed with CABA-201 with sufficient follow-up to be evaluable across the RESET clinical development program. In the RESET-Myositis trial, one patient in the immune-mediated necrotizing myopathy cohort completed six months of follow-up and two patients, one in the IMNM cohort and one in the dermatomyositis cohort, each completed one month of follow-up. In the RESET-SLE trial, one patient in the non-renal systemic lupus erythematosus cohort completed six months of follow-up, one patient in the lupus nephritis cohort completed four months of follow-up and two patients in the non-renal SLE cohort each completed one month of follow-up. Translational assessments from the third patient in the non-renal SLE cohort were not available for inclusion at the time of the data cut-off. In the RESET-SSc trial, one patient in the severe skin cohort completed six weeks of follow-up. Across these eight patients treated with CABA-201, patients were administered a one-time infusion of CABA-201 at 1 x 106 cells/kg, following a preconditioning regimen of fludarabine and cyclophosphamide. The primary endpoint of each trial is safety and tolerability within 28 days of infusion. Secondary endpoints include translational assessments and clinical outcomes. Safety and Tolerability Profile: CABA-201 has shown a favorable risk-benefit profile in patients with active and refractory autoimmune disease. Through 28 days of follow-up, no evidence of cytokine release syndrome of any grade was observed in five of the eight patients. Low-grade CRS was observed in three patients, all of which recovered following standard care. Tocilizumab was not administered for any cases of CRS. No evidence of immune effector cell-associated neurotoxicity syndrome of any grade has been observed in any patient since reporting the initial safety data on the first LN patient in August 2024. This patient had acute inflammatory events shortly before CABA-201 treatment and demonstrated an abnormal, pro-inflammatory cytokine profile prior to infusion that continued after CABA-201 infusion, suggestive of a possible occult infection. Translational Assessments: CABA-201 induced consistent and complete B cell depletion, with early naive B cell repopulation suggesting the potential to generate an immune system reset CAR T cell expansion associated with CABA-201 reached its peak between day 8 and day 15. Translational assessments from the first patient in the LN cohort indicated a second peak at day 29. Complete B cell depletion was observed by day 22 after CABA-201 infusion. B cell repopulation occurred in the first two patients treated with CABA-201 as early as 8 weeks and exhibited a transitional naive phenotype, reflecting the production of new B cells after deep systemic depletion. Two of the three patients with follow-up beyond three months demonstrated a reduction in disease-associated antibodies. Clinical responses in all three of these patients were observed independent of autoantibody levels. Vaccine and infectious pathogen antibodies remained generally stable. Clinical Outcomes: CABA-201 provided compelling signs of early efficacy, supporting the potential for drug-free clinical responses Initial clinical responses in the RESET-Myositis trial were consistent with published data with response kinetics appearing to differ between myositis subtypes. The first known adult DM patient dosed with CAR T in the form of CABA-201 demonstrated an improvement in muscle strength to normal and a major total improvement score response off all immunosuppressants at one month of follow-up. The Cutaneous Dermatomyositis Disease Area and Severity Index - Activity improved from 25 to 9. At six months of follow-up, the first IMNM patient demonstrated a continued and improved clinical response off immunosuppressants and without flares. At one month of follow-up, the second IMNM patient demonstrated a total improvement score consistent with the first IMNM patient at one month after CABA-201 infusion off immunosuppressants. All four patients in the RESET-SLE trial demonstrated clinical responses off immunosuppressants. All three patients in the non-renal SLE cohort demonstrated no clinical symptoms on SLEDAI-2K as of the latest follow-up and the first patient has completed a prednisone taper to discontinuation. The first patient in the LN cohort, who experienced the previously reported ICANS event, had a SLEDAI that improved from 22 at baseline to 8 at month four of follow-up. The patient's proteinuria improved more than 90%, approaching normal levels, while off all immunosuppressants and with an ongoing prednisone taper. The first patient in the severe skin cohort in the RESET-SSc trial demonstrated early clinical improvements after discontinuation of disease-specific therapy. The modified Rodnan Skin Score of the first patient in the severe skin cohort improved from 42 at baseline to 36 at day 42, suggesting the potential emergence of a drug-free clinical response.

07:34 EST Larimar Therapeutics presents Phase 1 and 2 dose studies of nomlabofusp - Larimar Therapeutics presented data from the company's Phase 1 studies and the Phase 2 dose exploration study of nomlabofusp in Friedreich's ataxia, or FA, at the International Congress for Ataxia Research in London, U.K. FA is an autosomal recessive neurodegenerative disorder caused by GAA repeats in the FXN gene that result in FXN deficiency. Nomlabofusp study participants were representative of the broad population of adults with FA. Treatment with nomlabofusp modified gene expression and lipid profiles in addition to increasing frataxin - FXN - levels in study participants with Friedreich's ataxia. Modeling and simulation predict that, in most patients with FA, 50 mg of nomlabofusp administered daily is likely to achieve FXN levels that are greater than or equal to50% of levels observed in healthy controls and similar to mean FXN levels reported in asymptomatic heterozygous carriers. Disease characteristics of adult participants in the nomlabofusp studies were representative of the broad population of adults with FA. Relationships between tissue FXN levels and onset of disease and GAA repeat length observed at baseline in nomlabofusp clinical study participants were consistent with prior published studies. A nomlabofusp program update is expected mid-December 2024.

07:30 EST Rhythm Pharmaceuticals announces five presentations at ESPE 2024 - Rhythm Pharmaceuticals announced the presentation of new, real-world data that showed four pediatric patients with acquired hypothalamic obesity or congenital hypothalamic obesity achieved greater than5% weight reduction at three months on setmelanotide, a melanocortin-4 receptor agonist. These data were among five Rhythm-related presentations delivered during the 62nd annual meeting of the European Society for Paediatric Endocrinology in Liverpool, England. 3-month real-world setmelanotide hunger and weight outcomes in four French pediatric patients with acquired or congenital hypothalamic obesity: The presentation includes results from four case reports of patients less than18 years old, two with acquired hypothalamic obesity and two with congenital hypothalamic obesity, at month three on setmelanotide therapy: Congenital hypothalamic obesity: Female, age 15, with septo-optic dysplasia as cause of hypothalamic obesity, achieved a body weight decrease of 9.6% from baseline at month 3 and BMI-Z score change from 3.1 at baseline to 2.8; Male, age 9, with pituitary stalk interruption syndrome as cause of hypothalamic obesity, achieved a body weight decrease of 5.2% from baseline at month 3 and BMI-Z score change from 3.7 at baseline to 3.5; Acquired hypothalamic obesity: Male, age 13, with acquired hypothalamic obesity related to craniopharyngioma resected at age 9, achieved a body weight decrease of 5.6% from baseline at month 3 and 9.5% weight reduction at month 6, and BMI-Z score change from 3.7 at baseline to 3.4 at month six of setmelanotide therapy; and Male, age 13, with acquired hypothalamic obesity related to radiotherapy for juvenile pilocytic astrocytoma, achieved a body weight decrease of 8.3% from baseline at month 3 and BMI-Z score change from 3.1 at baseline to 2.8. These patients were treated with setmelanotide at four different hospitals in France under a pre-marketing, early-access authorization program. All four patients remain on therapy, as of November 15, 2024, and there were no new safety signals observed. Also today, Rhythm announced plans for a new, 34-week substudy designed to evaluate setmelanotide in 39 patients with congenital hypothalamic obesity aged 4 years and older. Rhythm is seeking approval from the U.S. Food and Drug Administration for the independent substudy for congenital hypothalamic obesity as a protocol amendment to the Company's ongoing Phase 3 trial evaluating setmelanotide in patients with acquired hypothalamic obesity. Rhythm anticipates enrolling the first patients with congenital hypothalamic obesity in the first quarter of 2025. The substudy in congenital hypothalamic obesity is independent from Rhythm's pivotal Phase 3 trial in acquired hypothalamic obesity. The Company remains on track to disclose topline data from that pivotal trial in the first half of 2025. In a poster entitled, "Evaluating Setmelanotide Treatment for 12 Months in Pediatric Age Groups With Rare Melanocortin-4 Receptor Pathway-Related Obesity: Efficacy in Weight Reduction and Safety Outcomes," presenters highlighted the importance of early intervention in young patients with rare MC4R pathway diseases. A cross-sectional analysis of 50 patients aged 2 to 17 years with rare MC4R pathway diseases who participated in one of five different clinical trials of setmelanotide was presented showing that patients regardless of age achieved clinically meaningful weight reductions, and that children between 2 and 5 years old achieved a greater absolute BMI Z reduction. Additionally, the Company delivered three oral presentations based on analyses of more than 5,000 sequencing samples from the Company's European genetic testing program for individuals with suspected rare MC4R pathway diseases, Rare Obesity Advanced Diagnosis or ROAD. Genetic testing of individuals with early-onset obesity can help improve disease etiology understanding and identify patients who may benefit from specialized care. Highlights from these three presentations included: 1.74% of individuals tested carried a biallelic variant in one of 22 tested genes related to Bardet-Biedl syndrome and the frequency in Turkey was 5.82%, potentially due to consanguinity rates; 22.5% of tested individuals with early-onset obesity carried a variant classified as pathogenic, likely pathogenic or of unknown significance of one or more genes closely associated with MC4R pathway function: SIM1, SEMA3 family, PLXNA family, POMC, PCSK1, LEPR, SH2B1 and NCOA1; and 4.9% of tested individuals carried a biallelic or heterozygous pathogenic, likely pathogenic or VUS variant in one or more of these genes: ALMS1, BBS, MAGEL2, PHIP, or TBX3 genes. These genes are associated with certain debilitating syndromes.

07:26 EST Tonix Pharmaceuticals presents data, analyses of TNX-102 SL effects - Tonix Pharmaceuticals presented data in a poster presentation at the ACR Convergence 2024 Annual Meeting, held November 14-19, 2024, in Washington, D.C. A copy of the Company's presentation, titled "Randomized, Double-Blind, Placebo-Controlled Confirmatory Phase 3 Trial of Bedtime Sublingual Cyclobenzaprine in Fibromyalgia" is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com. In the Phase 3 RESILIENT study, TNX-102 SL met the pre-specified primary endpoint of significantly reducing daily pain compared to placebo in participants with fibromyalgia. In the RESILIENT study, TNX-102 SL demonstrated a broad spectrum of benefits with statistically significant improvement in all six pre-specified key secondary endpoints including those related to improved sleep quality, reduced fatigue, and improved patient global ratings and overall fibromyalgia symptoms and function. TNX-102 SL was generally well tolerated with an adverse event profile comparable to prior studies and no new safety signals observed. Tonix submitted a new drug application to the U.S. Food and Drug Administration in October 2024 for TNX-102 SL for the management of fibromyalgia. The FDA typically has a 60-day filing review period to determine whether the submitted NDA is complete and accepted for review. If the FDA accepts the NDA for review, the Company expects a 2025 date for a FDA decision on approval, based on the Prescription Drug User Fee Act.

07:24 EST EyePoint reports inducement grants under NASDAQ listing rule - EyePoint Pharmaceuticals announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 23,600 shares of EyePoint Pharmaceuticals common stock to four new employees. The stock options were granted on November 15, 2024. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $9.17 per share, the closing price of EyePoint Pharmaceuticals' common stock on November 15, 2024. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee's continued service with EyePoint Pharmaceuticals through the applicable vesting dates.

07:23 EST Immatics announces clinical data on TCER IMA402 targeting PRAME - Immatics is providing the first clinical data update from the ongoing Phase 1 dose escalation trial evaluating its next-generation, half-life extended TCR Bispecific molecule, TCER IMA402 targeting PRAME. Patient Population: As of the data cut-off on November 6, 2024, 33 heavily pretreated patients with recurrent and/or refractory solid tumors have been treated with a dose range from 0.02 mg to 4 mg of IMA402 monotherapy. The treated patient population is composed of patients with a median of three and a maximum of five lines of prior systemic treatments. The safety population includes all 33 patients treated with IMA402, of which 21 patients were evaluable for efficacy analysis and are PRAME-positive or were not tested for PRAME. Of these 21 patients, eight patients received at least one dose of IMA402 at dose level 7, and one patient received IMA402 at dose level 8. Based on preclinical in-vivo data, relevant anti-tumor efficacy was expected starting at ~3 mg human equivalent dose, which aligns with the initial clinical anti-tumor activity reported today. Safety: IMA402 demonstrated a favorable tolerability profile in the 33 patients treated. The most common treatment-related adverse events were mostly mild to moderate cytokine release syndrome and transient lymphopenia. Step dosing has been implemented and dose escalation is ongoing. The maximum tolerated dose has not yet been determined. Pharmacokinetics: Early pharmacokinetic data indicate a median half-life of approximately seven days, potentially enabling bi-weekly dosing. Initial Anti-Tumor Activity: Initial signs of clinical activity have been observed and are associated with PRAME expression and IMA402 dose levels administered. In the PRAME-negative patient population across all doses and indications, only one patient out of seven showed tumor shrinkage of -2.9%. In comparison, in the PRAME-positive or non-tested patients across all indications treated with low dose levels tumor shrinkage was observed in 25% of patients, including one unconfirmed partial response in a cutaneous melanoma patient. Nine patients with tumors that tested PRAME-positive or were not tested for PRAME received a relevant dose. 78% thereof experienced shrinkage of their target lesions, including several patients with significant ongoing tumor shrinkage: one cutaneous melanoma patient with an ongoing confirmed partial response with -40.2% tumor shrinkage treated at DL7; two patients with ongoing stable diseases with significant tumor shrinkage; one ovarian cancer patient with ongoing stable disease and tumor shrinkage of -13% started at DL6 and currently at DL7.

07:20 EST Bitdeer reports Q3 EPS (35c), consensus (19c) - Reports Q3 revenue $62.0M, consensus $79.60M. "This quarter marked a foundational period for Bitdeer, focused on the advancements of our key technological and strategic initiatives," stated Matt Kong, Chief Business Officer. "In our ASICs business, we made substantial progress in the commercialization of our SEALMINER mining rigs that will help diversify our revenue streams and accelerate the growth of our self-mining operations. For SEALMINER A1, the first sample batch was successfully energized and production of 3.7 EH/s is expected to be completed and installed into our datacenters in Texas and Norway in phases from December through Q1 2025 for the time being...Further, in October, we commenced mass production of our SEALMINER A2 series and the first production run is expected to deliver 18 EH/s, which will be used for self-mining and selling to external customers. Notably, SEALMINER A2 will be a significant milestone as we enter this multi-billion dollar market. We are already engaged in discussion with a number of potential customers, and early demand is promising, indicating strong interest in our cutting-edge technology and the industry's desire for supply chain diversification."

07:19 EST AmeriTrust appoints Troy Hocker as CRO - AmeriTrust announced the appointment of Troy Hocker to the position of Chief Revenue Officer. Troy is a seasoned automotive finance executive with over 20 years of industry experience at the largest direct to consumer leasing company in the country,

07:17 EST Halozyme provides update on proposal to combine with Evotec - Halozyme Therapeutics (HALO) provided an update on its non-binding proposal to acquire Evotec SE (EVO) for EUR 11.00 per share in cash, implying a fully diluted equity value of EUR 2.0 billion. In a presentation posted on its investor relations website, Halozyme highlights how its proposed combination with Evotec would create a leading global innovative pharma services company that would deliver significant value to all stakeholders. The presentation highlights include: The acquisition of Evotec would be a logical extension and diversification of Halozyme's business, and is aligned with Halozyme's M&A criteria: De-risked business; Structurally similar business model; Strong biopharma partnerships: Potential for durable long-term revenue growth. The combination would create a unique B2B global innovative pharma services company with complementary and leverageable platforms and cross-selling opportunities:Drug discovery; Continuous biologics manufacturing; Drug delivery. The combination would meaningfully diversify, scale and extend Halozyme's revenue and adjusted EBITDA well into the next decade and beyond: Establishes a diversified pharma services portfolio with approximately $2 billion in annual revenue projected in 2025. Enhances long-term growth profile. Delivers robust long-term margin profile. The all-cash transaction would be supported by an existing lender group with a clear path to less than 2x net leverage within two years post-close. Halozyme has significant cash reserves on-hand and a strong balance sheet with cash projected to be more than $800 million at year-end 2024.The transaction would not be subject to a financing condition.

07:16 EST Serve Robotics appoints Anthony Armenta as Chief Software & Data Officer - Serve Robotics appointed former Postmates and GM executive Anthony Armenta as Chief Software and Data Officer. Armenta re-joins Serve after previously spearheading early development of the company's autonomous robots as Vice President of Software Engineering at Postmates, prior to Serve's spin-off from Uber.

07:13 EST Adicet Bio:1st patient dosed in trial evaluating ADI-001 in autoimmune diseases - Adicet Bio announced that the first LN patient has been dosed in the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases. "Dosing the first lupus nephritis patient in our Phase 1 trial of ADI-001 marks an important step forward in our mission of improving the lives of patients affected by autoimmune diseases, particularly lupus nephritis," said Francesco Galimi, M.D., Ph.D., Senior Vice President and Chief Medical Officer of Adicet Bio. "With clinical biomarker data from our study in non-Hodgkin's lymphoma demonstrating robust tissue trafficking and complete CD19+ B cell depletion in peripheral blood and secondary lymphoid tissue, ADI-001 has the potential to be a transformative off-the-shelf treatment option for several autoimmune diseases. Additionally, the FDA's Fast Track Designation to ADI-001 in relapsed/refractory class III or class IV LN and the clearance of our investigational IND amendment application of ADI-001 for the treatment of SPS and IIM further serves to emphasize the broad and urgent unmet need for approved therapies to address autoimmune diseases." Dr. Galimi continued, "With clinical sites open for enrollment and additional sites that are expected to open in the near future, we anticipate sharing preliminary clinical data from the trial in the first half of 2025. In addition, we look forward to initiating enrollment for SLE, SSc, IIM, and SPS patients in the first quarter of 2025 and for AAV patients in the second half of 2025."

07:12 EST Globe Life board approved authorization to repurchase up to $1.8B of stock - Globe Life announced that its Board of Directors has approved an authorization to repurchase up to $1.8 billion of common stock under the Company's existing stock repurchase program. This authorization has no set time period and replaces the previous authorization of $1.3 billion announced on April 29, 2024.

07:10 EST Acurx supported, participated in Peggy Lillis CDI symposium - Acurx Pharmaceuticals announced its support and participation in the Inaugural Peggy Lillis Foundation Scientific Symposium, held on Friday, November 15, 2024. Acurx's Executive Chairman, Bob DeLuccia, delivered opening remarks for the symposium which assembled experts and thought leaders from around the world to present state-of-the art updates regarding C difficile Infection, CDI, and therapeutic options. Topics covered included epidemiology, bacterial physiology, risk factors for infections, and new and emerging treatment modalities. The Symposium also included testimonials from patients who survived CDI.

07:09 EST SBC Medical Group to acquire Aesthetic Healthcare, terms undisclosed - SBC Medical Group announced that it has entered into a definitive agreement to acquire Aesthetic Healthcare, a privately-held Singapore-based company that owns and operates several brands that provide aesthetic medical treatments in an all-cash transaction scheduled to close on November 13.

07:07 EST Wolfspeed CEO Gregg Lowe to depart - Wolfspeed announced that its board of directors has determined and agreed with Gregg Lowe that he will depart this month from his roles as Wolfspeed's president and CEO and as a member of the board. The board is conducting a search to identify a permanent CEO with the support of a global executive search firm. The board has appointed Thomas Werner, chairman of the board, as executive chairman while the board works to identify Wolfspeed's next CEO. Werner will oversee the continued execution of Wolfspeed's strategy in close alignment with Wolfspeed's senior leadership team, the board and the board's operations and finance committees. Following Werner's appointment as executive chairman, board member Stacy Smith was appointed as lead independent director.

07:06 EST Great American Group launches as new independent business - B. Riley Financial and funds managed by Oaktree Capital Management announced the launch of a partnership between B. Riley and Oaktree in the Great American Group, an industry-leading provider of valuation, appraisal, asset disposition and real estate services. Bryant Riley, Chairman and Co-Chief Executive Officer of B. Riley, said, "We are excited about this new partnership with Oaktree, which has the scale and expertise in alternative investments to power GA Group's next chapter of growth and success. The transaction provided B. Riley with the ability to meaningfully de-lever our balance sheet and retain significant equity upside in a business with compelling growth prospects."

07:03 EST Mind Medicine appoints Gregg Pratt chief regulatory, quality assurance officer - Mind Medicine announced the appointment of Gregg Pratt as chief regulatory and quality assurance officer. Pratt will serve as a member of the executive committee and oversee the company's regulatory and quality functions, as well as its product registration strategies. Pratt joins MindMed from Karuna Therapeutics.

07:02 EST Newmont announces sale of Musselwhite for up to $850M - Newmont Corporation (NEM) has agreed to sell its Musselwhite operation in Ontario, Canada, to Orla Mining (ORLA) for up to $850 million in total consideration. Under the terms of the agreement, Newmont will receive cash consideration of $810 million upon closing and up to $40 million in contingent payments. The transaction is expected to close in the first quarter of 2025, subject to certain conditions being satisfied. Upon closing the announced transactions, Newmont will have surpassed its target of delivering more than $2 billion in gross proceeds from non-core divestitures. In February 2024, Newmont announced the intent to divest its non-core assets, including six operations and two projects from its Australian, Ghanaian, and North American business units. With definitive agreements in place to divest the assets in Australia, Ghana, and now Musselwhite, the Company is focused on completing the sales processes for its other North American non-core assets, which are expected to conclude in the first quarter of 2025.Total gross proceeds from transactions announced in 2024 to date are expected to be up to $2.9 billion. This includes $2.3 billion from non-core divestitures and $527 million from the sale of other investments, detailed as follows: Up to $475 million from the sale of the Telfer operation and Newmont's 70% interest in the Havieron project; Up to $1.0 billion from the sale of the Akyem operation; Up to $850 million from the sale of the Musselwhite operation; and $527 million from the completed sale of other investments, including the sale of the Lundin Gold stream credit facility and offtake agreement, and the monetization of Newmont's Batu Hijau contingent payments. Newmont continues to leverage free cash flow from its operations and proceeds from divestitures to enhance long-term value for shareholders by repurchasing shares on a ratable basis. In line with this strategy, the Company has an aggregate $3 billion share repurchase program authorized for execution through October 2026. Since October 24, 2024, Newmont has repurchased 7.2 million shares, totaling $336 million. Since the program's inception, Newmont has repurchased 22.4 million shares, amounting to $1.1 billion. This ongoing progress reflects Newmont's commitment to delivering meaningful returns and lasting value to shareholders. Additionally, Newmont has made significant progress toward reaching its targeted debt balance of $8 billion, retiring approximately $500 million of debt in 2024 and demonstrating the Company's dedication to a disciplined and balanced approach to capital allocation.

06:57 EST Neurogene provides update on NGN-401 clinical trial for Rett syndrome - Neurogene announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of Rett syndrome. On November 11, Neurogene became aware of an emerging treatment-related serious adverse event, or SAE, in a trial participant who received NGN-401 at a dose of 3E15 vg, high-dose cohort. This participant, who was dosed on November 5, subsequently experienced signs of a systemic hyperinflammatory syndrome, a rare and life-threatening immune response that has been reported with systemic exposure to high doses of AAV. The participant is in critical condition, and the case is continuing to evolve. The FDA completed a review of the safety data for NGN-401 and allowed Neurogene to proceed with the Phase 1/2 trial using the 1E15 vg dose - low-dose cohort -. Neurogene paused further use of the 3E15 vg dose upon initial notification of the SAE and does not plan to enroll any further participants at the 3E15 vg dose level. To date, there have been no other treatment-related SAEs in the clinical trial. All treatment-related AEs in the low-dose cohort have been mild. There have been no signs or symptoms indicative of MeCP2 overexpression toxicity. Neurogene no longer anticipates completing enrollment in the low-dose cohort of NGN-401 in Q4 as the company updates the protocol to reflect the discontinuation of the 3E15 vg dose.

06:55 EST Liberty Energy comments on nomination of CEO as U.S. Secretary of Energy - Liberty Energy commented on the announcement by President-elect Donald Trump regarding his nomination of Chris Wright, Liberty's Founder, Chairman of the Board, Director and CEO, for the position of U.S. Secretary of Energy. The appointment of Mr. Wright as Secretary of Energy is subject to confirmation by the U.S. Senate, and Mr. Wright will continue in his current positions with the Company until confirmation occurs. Effective upon and subject to this confirmation and in accordance with the Company's succession plan, the Board of Directors intends to appoint William Kimble as non-executive Chairman of the Board and Ron Gusek as CEO. Mr. Kimble has been a member of the Board of Directors since the Company's initial public offering in January 2018 and has served as Lead Director since October 2018. Mr. Gusek joined Liberty in 2014 and has served as President of the Company since November 2016.

06:53 EST Oscar Health says Mark Bertolini's foundation purchases 933,333 shares - Oscar Health announced that the Anahata Foundation, a charitable foundation established by Mark T. Bertolini, Oscar's CEO, purchased 933,333 shares on the open market the week of November 11, 2024. Oscar was not a party to any of these transactions.

06:50 EST Target Hospitality extends contract with Pecos Children's Center - Target Hospitality announced the extension and amendment of the company's Pecos Children's Center, or PCC, contract, reaffirmed its previously announced 2024 financial outlook and enhanced its strategic capabilities. The PCC contract extension and amendment, effective November 16, supports a community capable of serving up to 6,000 individuals and will represent annual minimum lease revenue of approximately $168M. The PCC Contract continues to provide for additional occupancy based variable services revenue depending on active community population. However, given the dynamic fluctuations in community population, Target believes it prudent to continue excluding any incremental PCC variable revenue from its 2024 outlook. The company has engaged Carla Provost, a former chief of the United States Border Patrol under the previous Trump administration, to serve as a strategic advisor and government liaison. With over 25 years of service in the U.S. Border Patrol, the company believes Provost's knowledge and experience will provide insight as Target actively evaluates multiple government focused strategic growth initiatives.

06:50 EST Invitation Homes announces $200M joint venture - Invitation Homes has entered into an agreement to form a new joint venture partnership with a global real estate investment partner. The JV will leverage the company's homebuilder partnerships, management expertise, and scale to invest in newly-constructed homes and communities in several high-growth markets. The JV is expected to deploy approximately $500M , including debt, to acquire newly constructed homes. The JV will be initially capitalized with a total equity commitment of $200M, of which $50M will be committed by Invitation Homes, with potential to upsize equity commitments through follow-on investment tranches in the future. The company will provide various management services to the JV, for which the company will earn management fees in addition to the opportunity to earn a promoted interest subject to certain performance thresholds. Invitation Homes also has certain rights to potentially acquire the JV's homes in the future.

06:36 EST Tuya announces investment by 65 Equity Partners - Tuya announced that a definitive agreement has been entered into in respect of a strategic investment by 65 Equity Partners through its purchase of an approximate 13% of Tuya's total issued shares from New Enterprise Associates. 65 Equity Partners is an independently managed wholly-owned investment platform of Temasek dedicated to supporting founders in their growth journey. The firm focuses on investing in family-owned and entrepreneur-led businesses in Southeast Asia, Europe and the United States across the technology, business services, consumer, industrials and healthcare sectors.

06:34 EST Graphex Group receives extension to comply with Nasdaq continued listing rules - Graphex Group received an extension from the NYSE American for an additional period to regain compliance with the NYSE American listing rules for American Depository Shares on the Exchange until May 15, 2025. The Company did not timely file with the Securities and Exchange Commission its Form 20-F for the year ended December 31, 2023. The initial cure period for the Company to maintain its listing of its ADS listed on the Exchange expired on November 15, 2024. The listing of the ADSs continues on the Exchange during the Additional Cure Period pursuant to this extension, subject to the Company's compliance with other continued listing requirements and the NYSE Regulation Staff's review of the Company's efforts to regain compliance with the Exchange's continued listing standards. The expiration of the initial cure period and the grant of the Additional Cure Period by the Exchange does not affect the Company's business operations or its reporting obligations under the Securities and Exchange Commission regulations and rules. The Company plans to file the Delayed Filing as soon as possible and in any event within the Additional Cure Period. However, there can be no assurance that the Company will ultimately regain compliance with all applicable Exchange listing standards.

06:33 EST LVMH appoints Alvarez-Pereyre as VP HR, Guiony as CEO Moet Hennessy - After consulting with the Sustainability and Governance Committee of the Board of Directors, Bernard Arnault, Chairman and Chief Executive Officer of LVMH, has decided to make the following appointments: Maud Alvarez-Pereyre will be appointed Executive Vice President Human Resources, VP HR, of the LVMH Group and become a member of the Executive Committee, effective December 1, 2024. Jean-Jacques Guiony, a member of the Executive Committee, will be named President and Chief Executive Officer of the Wines and Spirits division, Moet Hennessy, effective February 1, 2025. He replaces Philippe Schaus who, after 21 years with the Group, has decided to begin a new chapter in his career, focusing on non-executive roles. Jean-Jacques Guiony will be accompanied by Alexandre Arnault as Deputy CEO of the division, as of February 1, 2025. Charles Delapalme will be appointed President and Chief Executive Officer of Hennessy following a period of transition with Laurent Boillot, whose new responsibilities will be announced at a later date. Cecile Cabanis, a member of the Executive Committee, will be appointed Chief Financial Officer of the LVMH Group, succeeding Jean-Jacques Guiony as of February 1, 2025. In addition, Guillaume Motte, President and Chief Executive Officer of Sephora, will be named a member of the Executive Committee effective January 1, 2025.

06:31 EST AstraZeneca's Tagrisso recommended for approval in EU by CHMP for certain NSCLC - AstraZeneca's Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer, or NSCLC, whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy, or CRT, the company announced.

06:09 EST Liberty Gold announces results from field sampling at Antimony Ridge discovery - Liberty Gold announced the completion of a first pass field sampling program at the Antimony Ridge discovery, part of the Company's Goldstrike Oxide Gold Project in southwestern Utah. Following a strategic staking program that added 3.2 square kilometers to the Goldstrike claim block in September, recent field work has confirmed the presence of significant high-grade antimony and gold oxide mineralization at surface. A follow-up detailed surface sampling and mapping program has been initiated to better define the key target areas and exploration drill testing is being planned for 2025. Pete Shabestari, Vice President, Exploration, commented: "Our successful fieldwork at Antimony Ridge confirms the high-grade potential of this discovery, not only for antimony but for gold as well. This program demonstrates our commitment to unlocking value from all parts of the Goldstrike project. We look forward to advancing Antimony Ridge into the next phase of exploration with an expanded field program and preparation for drilling in 2025." Key Sampling Results and Discoveries: Liberty Gold's recent fieldwork has significantly increased the size and grade of the identified antimony mineralized zone at Goldstrike, with new sampling returning values of up to 5.7% antimony and 3.94 grams per tonne gold, surpassing previous high-grade results of 2.0% antimony and 0.84 g/t gold. A total of 112 surface samples were taken from across the 6 square kilometer target area. The known high-grade mineralized zone is hosted within a laterally extensive jasperoid breccia body. The known mineralized zone spans greater than 450 meters along strike length and is five to locally over 10 meters thick. Sampling has been focused on areas of good exposure and regionally, the jasperoid is present throughout the eastern area at the contact between Eocene sediments and Miocene volcanics and dips 20-25 degrees to the northeast. In addition to mapping and sampling at the main antimony and gold zone, the field program discovered a 300 meter exposure of mineralized jasperoid breccia area 1,500 meters to the east, along the same contact.

06:06 EST iHeartMedia announces exchange offers, consent solicitations for existing notes - iHeartMedia announced the November 15, 2024 commencement of exchange offers for iHeartCommunications, Inc.'s outstanding 6.375% Senior Secured Notes due 2026, 5.250% Senior Secured Notes due 2027, 4.750% Senior Secured Notes due 2028 and 8.375% Senior Notes due 2027, and concurrent consent solicitations to amend certain provisions in the indentures governing the Existing Notes pursuant to the terms and conditions described in a Confidential Offering Memorandum and Consent Solicitation Statement, dated November 15, 2024. Eligible Holders of the Existing Notes may not deliver consents in the Consent Solicitations without tendering their Existing Notes in the Exchange Offers. Concurrently with, but separately from, the Exchange Offers and Consent Solicitations, the Company also announced the commencement of an exchange offer for Communications' outstanding term loans and a consent solicitation to amend certain provisions in the credit agreement governing the Existing Term Loans in connection with the Term Loan Exchange. Pursuant to a Transaction Support Agreement entered into by the Company, certain of its subsidiaries and certain lenders and holders of the Existing Debt as of November 14, 2024, Supporting Holders representing approximately 85.4% of the aggregate principal amount of the Existing Debt, including approximately 84.1% aggregate principal amount of the Existing 2026 Secured Notes, approximately 89.5% aggregate principal amount of the Existing 2027 Secured Notes, approximately 40.9% aggregate principal amount of the Existing 2028 Secured Notes, approximately 82.8% aggregate principal amount of the Existing Unsecured Notes and approximately 95.3% aggregate principal amount of the Existing Term Loans, have agreed to tender and provide consents with respect to their Existing Notes in the Exchange Offers and Consent Solicitations and exchange and provide consents with respect to their Existing Term Loans in the Term Loan Exchange and Term Loan Consent Solicitation. Simpson Thacher & Bartlett LLP served as counsel and PJT Partners served as financial advisor to the Company. Davis Polk & Wardwell LLP served as counsel and Perella Weinberg Partners served as financial advisor to an ad hoc group of certain of the Supporting Holders.

06:02 EST Hims & Hers names Deb Autor to board, Janet Stevens as head of quality, safety - Hims & Hers Health, announced Deb Autor, former deputy commissioner at the FDA, will join the company's board of directors, and Janet Stevens, a pharmaceutical quality expert, will join the company as Global Head of Quality & Safety. Autor previously served as the Deputy Commissioner for Global Regulatory Operations and Policy at the FDA, where she oversaw FDA inspections, criminal investigations, and international operations for the agency. She also served as the agency's Director of the Office of Compliance for the Center for Drug Evaluation and Research, leading enforcement for drug requirements. Stevens joins Hims & Hers from Hillrom, where she served as the Chief Quality Officer, helping the company achieve top-quartile results in global quality regulations.

05:43 EST BridgeBio announces publication of PROPEL 2 data in NEJM - BridgeBio announced that 18-month results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, were published as an original research article in the New England Journal of Medicine, or NEJM. Infigratinib is an investigational oral small molecule designed to inhibit FGFR3 signaling and target achondroplasia at its source. These data, which were also presented at the 62nd Annual European Society for Paediatric Endocrinology, or ESPE, meeting in Liverpool, demonstrate continued efficacy and a safety profile as an oral treatment option. Key results from the PROPEL 2 dataset were presented at ESPE in a talk titled "Oral infigratinib for children with achondroplasia: Month 18 results from the PROPEL 2 study demonstrate safety and durability of treatment effect on linear growth with improved body proportionality" by Melita Irving. The key data that were shared included: Statistically significant increase in annualized height velocity, or AHV, was observed in children in Cohort 5 who received a daily dose of 0.25 mg/kg/ day of infigratinib, with a mean change from baseline in AHV of +2.50 cm/year at Month 18. Mean change from baseline in height Z-score was +0.54 relative to an untreated achondroplasia population at Month 18. Statistically significant improvement in body proportionality was -0.12 at Month 18. Oral infigratinib was well tolerated at Month 18, with no serious adverse events or treatment-emergent adverse events leading to treatment discontinuation. Additionally, there was no accelerated progression of bone age, negative changes in bone mineral density, or other bone-related adverse events observed.

05:33 EST Corpay extends partnership with World Aquatics - Corpay announced that Corpay's Cross-Border business has entered into a multi-year agreement to extend their collaboration with World Aquatics as their Official FX Payments Supplier.

05:27 EST AbbVie receives EC approval of Elahere - AbbVie announced the European Commission, or EC, granted marketing authorization for Elahere for the treatment of adult patients with folate receptor-alpha, or FRa, positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. Elahere is the first and only folate receptor alpha-directed antibody drug conjugate medicine approved in the European Union, as well as Iceland, Liechtenstein, Norway, and Northern Ireland.

05:22 EST BioCryst launches Orladeyo in ireland - BioCryst announced that the Health Services Executive, or HSE, in Ireland has recommended Orladeyo for the routine prevention of recurrent attacks of hereditary angioedema, or HAE, in eligible patients 12 years and older. With this recommendation, HAE patients in Ireland will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks. The HSE decision in Ireland follows the European Commission marketing authorization of Orladeyo in April 2021. To date, Orladeyo is licensed in 44 countries.

05:15 EST NCR Atleos, NatWest Group expand relationship - NCR Atleos (NATL) announced that NatWest Group (NWG) has expanded its relationship with NCR Atleos to transform its self-service banking channel. As part of its commitment to modernization and improving customer experiences, the organization identified the need for a more agile and efficient self-service banking platform. Through its collaboration with NCR Atleos, NatWest Group is in the process of upgrading its owned and partner network of more than 5,500 ATMs and multi-function devices. This refresh will streamline NatWest Group branch and self-service operations, optimize availability and enable faster deployment of new transactions and services. The program includes the replacement of all NatWest owned ATMs and multi-function devices with new NCR Atleos technology that will provide a new innovative customer interface presented on 19" touchscreen displays.

05:04 EST Spirit Airlines issues letter to shareholders - Spirit Airlines issued the following open letter to all Spirit guests: "We are writing to let you know about a proactive step Spirit has taken to position the company for success. Spirit has entered into an agreement with our bondholders that is expected to reduce our total debt, provide increased financial flexibility, position Spirit for long-term success and accelerate investments providing Guests with enhanced travel experiences and greater value. Part of this financial restructuring includes filing a "prearranged" chapter 11. The most important thing to know is that you can continue to book and fly now and in the future. We also want to assure you: You can use all tickets, credits and loyalty points as normal. You can continue to benefit from our Free Spirit loyalty program, Saver$ Club perks and credit card terms. Our amazing Team Members are here to offer you excellent service and an elevated experience. We expect to complete this process in the first quarter of 2025 and emerge even better positioned to deliver the best value in the sky. Other airlines that are operating successfully today have undertaken a similar process. For more information about our financial restructuring, please visit www.SpiritGoForward.com. We're grateful you continue to choose Spirit for your travel needs. As we head into the holiday season and beyond, we look forward to welcoming you on board again soon."